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Abstract
Alcohol use disorder (AUD) is a prevalent neuropsychiatric disease with profound health, social,
and economic consequences. With an estimated 50% heritability, identifying genes that engen-
der risk and contribute to the underlying neurobiological mechanisms represents an important first
step in developing effective treatments. Gene expression studies are an important source of can-
didate genes for studying AUD, providing windows into the molecular machinery engaged by the
brain in response to ethanol. Our laboratory has implicated N-myc down-regulated gene 1 (Ndrg1)
as a potential candidate gene that modulates ethanol-induced changes in myelin-related gene ex-
pression and acute sensitivity to ethanol. Analysis of mPFC expression data found that Ndrg1
expression was positively correlated with voluntary ethanol intake across the BXD panel of mice
and demonstrated that the basal levels of Ndrg1 mRNA expression in the mPFC across seven dif-
ferent strains of mice was inversely correlated with LORR duration time. We found that mPFC
Ndrg1 expression was upregulated following 5 weeks of intermittent ethanol access in C57BL/6J
(B6J) mice. We also observed an induction of Ndrg1 in the mPFC of female B6J mice following
acute ethanol exposure. After observing the regulation of Ndrg1 in wild type mice, studies were
performed in a mouse line that produces a myelinating cell-selective conditional knockout (KO)
of Ndrg1, by inducing Cre Recombinase with tamoxifen treatment. Our findings demonstrate that
Ndrg1 expression and its functional state, as determined by phosphorylation state and localization,
are clearly modulated by acute ethanol.. We also found that deletion of Ndrg1 in myelinating cells
alters ethanol-related behaviors in a way that suggests sensitivity to ethanol is modified. Addition-
ally, we found altered ethanol concentration preferences and total ethanol preference between the
KO and control groups in a 5-week drinking study. Mutations in Ndrg1 result in a demyelinating
polyneuropathy: Charcot-MarieTooth Disease 4D. Given that mutations in Ndrg1 are known to
cause peripheral neuropathies in multiple species, we characterized the peripheral nerve dysfunc-
tion that develops from conditional deletion of the gene in adult aged mice. Additionally, some
evidence in clinical literature had suggested that nerve tissue levels of NDRG1 inversely correlates
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with chemotherapy-induced peripheral neuropathy (CIPN) following treatment with Paclitaxel for
breast cancer. We demonstrated that low dose Paclitaxel accelerates the development of neuropa-
thy symptoms in mice that have had Ndrg1 knocked out. The literature and our results suggest
that cellular bio-lipids and lipid interactions with BK channels, such as Kcnma1, are key drivers
for both the peripheral nerve dysfunction and the changes in ethanol sensitivity, but more stud-
ies are needed to prove this hypothesis. These results demonstrated the importance of Ndrg1 for
peripheral nerve function and demonstrated that decreasing levels of Ndrg1 do increase the toxic
effects of chemotherapeutics. Ultimately, the works presented here demonstrate the biological im-
portance of Ndrg1 in the maintenance of peripheral nerve function and as an ethanol-related gene
that modulates ethanol sensitivity, consumption, and risk for developing an AUD.
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Chapter 1
Introduction
In the United States, 17 million adults (7.2% of the population 18 years or older) met the criteria
for having an Alcohol Use Disorder (AUD) in 2012 (SAMHSA 2013). AUD is a clinical diagnosis
that encompasses a spectrum ranging from mild problem drinking to severe alcohol dependence,
according to DSM-V (American Psychiatric Association 2013). Long term abuse of alcohol leads
to end organ damage, abusive behaviors, and results in excessive and compulsive consumption
(Osna and Kharbanda 2016). Alcohol abuse is the third highest cause of preventable deaths in
the United States, following tobacco use and unhealthy diet (Mokdad 2004). Even though the
burden of alcohol abuse on society is large, there have been few medical interventions that suc-
cessfully treat the disease. In fact, it is estimated that less than 20% of alcoholics achieve sustained
abstinence with current approaches (Thompson and Lande 2018).
Multiple studies in animal models and humans have made it clear that gene expression, espe-
cially in the basal state before any ethanol exposure, contributes to the molecular and behavioral
response to ethanol and the propensity to develop AUD. Additionally, it is estimated that 50% of
the risk for developing alcohol dependence can be attributed to genetic predisposition (Goodwin
1974; Prescott and Kendler 1999). In particular, genetic factors that alter the magnitude of gene
expression, basally or in response to ethanol, are considered to be part of the mechanisms that
result in a predisposition for developing alcohol dependence (Chesler et al. 2005). While much re-
mains unknown regarding all the actions of ethanol, it is known that acute ethanol interacts directly
with many ligand-gated ion channels, such as GABA and NMDA receptors. Furthermore, the gene
expression of these ion channels are regulated by both acute and chronic ethanol exposure (Farris
and Miles 2013). Given that these receptors play a crucial role in behavioral responses to ethanol,
it suggests that genomic-level gene expression analysis can provide additional novel targets for
genes that modulate ethanol behaviors and may contribute to genetic risk for AUD.
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In another example of the relationship between ethanol, gene expression and mechanisms of
AUD, alcoholic patients are likely to face myelin-related sequelae after years of abuse. Patho-
logic studies of postmortem alcoholic brains have revealed white matter atrophy, particularly in
the frontal cortex (Kril et al. 1997). Early microarray analysis of postmortem frontal cortex of
human alcoholics found that several myelin-related genes are significantly down regulated relative
to control (Lewohl et al. 2000). Latter neuroimaging studies of living alcoholics confirmed white
matter deficits in vivo (Zahr and Pfefferbaum 2017). While the greatest white matter reductions
were observed in the mPFC, there are several other myelin related disorders that affect chronic
alcoholics. The most common neurological disorders and the selective areas of the brain where the
white matter or the gray matter damage is most severe are highlighted in Figure 1.1. This shows the
deleterious effects of alcohol abuse on myelin is widespread throughout the central nervous sys-
tem. In addition, chronic abuse of ethanol results in damage to a number of different tissue types,
including: skeletal and cardiac muscle, liver, immune system and both the central and peripheral
nervous systems (Chopra and Tiwari 2012).
Figure 1.1: Brain areas affected by alcohol-induced neurological conditions. Of note,
Marchiafava-Bignami disease (MBD), Wernicke’s Encephalopathy, and Liver Disease all affect
white matter within the corpus callosum. Central pontine myelinolysis (CPM) also affects white
matter in a distinctly different region of the brain. Figure from: Zahr and Pfefferbaum 2017.
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Chronic excessive consumption of ethanol has been shown to produce a peripheral neuropathy.
In the beginning stages, patients present with complaints of pain that results in allodynia, hyperal-
gesia, and a burning or tearing pain, especially in the lower extremities (Koike et al. 2001). Unfor-
tunately, alcohol-induced neuropathies respond poorly to existing pharmacotherapies (Chopra and
Tiwari 2012). Alcoholism-related thiamine deficiency leads to nervous system damage in cases
such as Beriberi neuropathy and Wenicke-Korsakoff disease, but is not the cause of many cases of
alcohol-induced neuropathy. Interestingly, a study of patients with alcohol neuropathy and normal
thiamine levels found small myelinated and unmyelinated nerve fiber density to be more severely
affected than large myelinated fiber density (Koike et al. 2001). This reduced nerve fiber density,
along with pathologic and eletrophyisologic evidence, suggest an axonal neuropathy (Koike et al.
2001). Additionally, thiamine-induced neuropathy has prominent subperineurial edema between
the perineurium and the endoneurial compartments, while widening of the distance between nodes
of Ranvier results in the segmental demyelination and remyelination (Koike et al. 2003). These
findings suggest that alcohol-induced neuropathy is caused directly by the toxic actions of ethanol
or the resulting metabolites, rather than thiamine deficiency.
As mentioned above, genetic factors have a major influence on susceptibility to developing an
AUD (Kalsi et al. 2009). In particular, it has been hypothesized that genetic determinants modu-
lating sensitivity to the intoxicating effects of acute ethanol exposure are an important risk factor
for developing an AUD (Schuckit et al. 1994; Gilman et al. 2012). Our laboratory has identified a
novel myelin-related candidate gene, Ndrg1, that is regulated at the level of mRNA abundance by
both acute and chronic ethanol exposure (Kerns et al. 2005; Bogenpohl et al. 2019). Furthermore,
NDRG1 protein phosphorylation is also regulated by acute ethanol treatment in mice (Costin, De-
ver, and Miles 2013). Ndrg1 encodes the alpha/beta hydrolase: N-myc down- regulated gene 1
(NDRG1). The NDRG1 protein is typically found in the cytoplasm of many different cell types
and it is thought to be involved in cellular stress responses, cancer related signaling pathways, and
cell trafficking, particularly in myelin-producing cells (Berger et al. 2004). Mutations in NDRG1 in
humans underlie Charcot-Marie-Tooth disease type 4D, an autosomal recessive demyelinating pe-
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ripheral neuropathy and immunocytochemistry studies show high levels of NDRG1 expression in
areas enriched in myelin (Okuda, Kokame, and Miyata 2008). While the exact function of NDRG1
is still unknown, multiple animal model studies have shown that modulation of Ndrg1 expression
can produce variation in myelin structure and function, particularly in the peripheral nervous sys-
tem (Okuda et al. 2004), but also in the central nervous system of humans (Echaniz-Laguna et al.
2007).
The studies described above suggest that myelin basal expression is an important determinant
of acute sensitivity to ethanol and hence, to the risk for abusive ethanol consumption. They further
suggest that ethanol can regulate myelin expression and that Ndrg1 is a potential key gene involved
in this response. We hypothesize that Ndrg1 expression is an important factor determining sensi-
tivity to ethanol and that regulation of Ndrg1 by ethanol exposure may have a role in the long term
risk for abusive consumption. As individuals progress from initial ethanol exposure to clinical
alcoholism, we also hypothesize that fundamental changes occur in the physiological and behav-
ioral responses from initial versus chronic ethanol exposure. Additionally, we also hypothesize
that changes in myelin related gene expression during this transition, in part, drive alterations in
behavioral responses to ethanol, such as the sensitivity to both the rewarding and aversive effects of
ethanol, thus resulting in escalating consumption of ethanol over time. We proposed the following
specific aims to test these hypotheses: (1) To determine whether acute and chronic ethanol show
differential effects on the gene expression, protein expression, or protein activity of a previously
identified genetic hub of ethanol responsive myelin-relates network in mPFC, Ndrg1. (2) To deter-
mine whether genetic modulation of Ndrg1 in myelin-producing cells alters ethanol-related behav-
iors, particularly ethanol consumption, and determine how loss of Ndrg1 in oligodendrocytes alters
brain gene expression. (3) Study the peripheral effects of Ndrg1 deletion on sciatic nerve function
and sensitivity to noxious stimuli, such as repeated high doses of ethanol and chemotherapeutics.
Additionally, this will be the first study to fully characterize the cell biology of NDRG1 in the
CNS, and document ethanol regulation of Ndrg1 in both male and female mice. Given that male
and female humans have differing responses to ethanol and that there are documented differences
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in the risk factors for alcohol use disorders between the sexes (Nolen-Hoeksema 2004), these
studies may aid in identification of sex-specific molecular risk factors for AUD.
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Chapter 2
Background and Significance
2.1 Sensitivity to alcohol and future risk
Human and animal studies have demonstrated that subjects with a “low” response to alcohol’s
effects following acute challenge have an increased risk for increased ethanol consumption and
the later development of alcohol dependence (reviewed in Crabbe, Bell, and Ehlers 2010). The
authors note that for the human participants, response to alcohol was measured by alterations in the
physiological, motor, and mood responses following after drinking a standardized dose of ethanol.
The degree of response relative to the ethanol dose provided can be considered as the sensitivity to
effects of ethanol intoxication.
Differences in sensitivity to acute ethanol, especially the adverse effects, alters the risk of
developing an AUD (Schuckit et al. 1994). In particular, individuals with low levels of response
to acute ethanol are at increased risk for later development of alcohol abuse (Schuckit et al. 1994).
While the immediate sensitivity to alcohol is very important in determining the response level to
alcohol, the individual’s capacity to develop tolerance to the acute challenge of ethanol is also an
important component of the “response level” of the individual (Blednov et al. 2018). Previous
work had already identified that PDE4 inhibitors, such as apremilast, led to decreases in ethanol
consumption and preference in B6 mice (Blednov et al. 2014). It was determined that apremilast
increased the LORR duration and recovery from the effects of ethanol on motor coordination,
and the drug led to increases in conditioned place avoidance to ethanol (Blednov et al. 2018).
The authors conclude that apremilast increases “level of response” to aversive effects of ethanol,
and this leads to the decreases in consumption and preference that were observed in their prior
publication (Blednov et al. 2018).
There is also an interplay between initial (acute) sensitivity to alcohol and acute functional
tolerance (AFT) to ethanol. Acute functional tolerance is a measure of the BEC at which the
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recovery of function occurs after intoxication from acute ethanol. The higher the BEC at the
recover or function, the higher the AFT to the measured task. In a study with mice that have been
bred for high alcohol preference and low alcohol preference, the high preference mice had a higher
initial sensitivity and a very fast development of AFT to the ataxia that follows ethanol (Fritz,
Grahame, and Boehm 2013). While this finding may seem counter to earlier works regarding
acute sensitivity and risk of increased ethanol consumption, this a logical outcome if AFT and
acute sensitivity are both elevated. For example, if one considers a subject that is very sensitive
to the initial effects of ethanol, which can be both the rewarding and the adverse effects, but that
quickly recovers from the adverse effects of acute ethanol. Following the AFT to the adverse
effects of ethanol, the subject would continue to experience the rewarding aspects of ethanol rather
since tolerance has developed to the adverse effects that would limit further consumption of ethanol
during the drinking session.
It is also documented that sensitivity to the adverse effects of ethanol has a protective effect
for the abuse risk. Individuals with SNPs in the genes responsible for ethanol metabolism, alcohol
dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), have reduced risk of developing an
AUD (Edenberg 2007). This is due in part to the fact that deficits in ethanol metabolism likely al-
ter acute sensitivity to ethanol since the pharmacokinetics of ethanol will be altered. Acetaldehyde
(ACD) is a toxic byproduct of ethanol metabolism. In addition to being a known carcinogen, ACD
is responsible for many of the adverse physical effects of excess ethanol consumption in the periph-
ery (Deehan, Brodie, and Rodd 2013). Interestingly, the authors acknowledge there is a debate if
ACD crosses the blood brain barrier and if it is an important contributor to the reinforcing effects of
ethanol consumption, as other literature claims these adverse central effects are mediated by both
ACD and acetate (Pardo et al. 2013). This group demonstrated that the downstream metabolite of
ACD, acetate, also contributes to ethanol behaviors and modulates the effects of ethanol within the
CNS (Pardo et al. 2013). Interestingly, these authors found that while prolonged consumption of
acetate did not alter the onset or the duration of LORR, it did significantly decrease the number of
mice that actually lose their righting reflex (LORR), a test of acute ethanol sensitivity, following
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a large dose of ethanol. In addition, 15 days of acetate administration amelorated ethanol induced
changes in locomotor activity without altering basal open field locomotion (Pardo et al. 2013).
2.1.1 Measures of sensitivity to ethanol
There are many available methods for measuring sensitivity to ethanol in humans and mouse
models. In humans, sensitivity to ethanol can be studied by measuring sway characteristics while
standing on a force platform following acute exposure (Kitabayashi et al. 2004). Total locomotor
activity frequently altered by acute ethanol exposure in many strains of mice. The ability to remain
on the rotating stage of a Rotarod machine is impaired by moderate to high doses of ethanol.
One of the important measures of sensitivity to alcohol is rodent models is the loss of righting
reflex (LORR). Rodents have a remarkable ability to right themselves from the supine to the prone
position almost instantly. Following a high dose of ethanol (e.g., greater than 3.8g/kg, i.p.), this
ability is temporarily lost before it is regained. This test measures the onset or latency until LORR
is achieved and the duration of time until the righting reflex is regained. Additionally, blood can
be drawn immediately after the onset of LORR, and again immediately after the righting reflex is
recovered. The time to the onset of LORR and the BEC at the onset can be considered a measure of
acute sensitivity to ethanol, while the duration of LORR and the BEC at the recovery of the righting
reflex (RORR) can be considered a measure of acute functional tolerance. Additionally, LORR can
be performed multiple times or after voluntary drinking to get further measures of tolerance, which
can be predictive of future issues with alcohol dependence.
2.2 Identification of candidate genes / networks involved in risk of alco-
holism
As discussed in Chapter 1, it is estimated that 50% of the risk for developing alcohol depen-
dence can be attributed to genetic predisposition (Goodwin 1974; Prescott and Kendler 1999). The
studies above regarding the metabolism of ethanol illustrate the presence of deleterious SNPs in
genes that encode for ethanol metabolism (ADH and ALDH) can have strong effects on behav-
ioral sensitivity to ethanol. These alterations in sensitivity to the effects of ethanol exposure play
a large role in predicting the risk of later development of alcohol dependence. Thus, it begged to
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ask if additional SNP variants could be correlated with AUD using human genome-wide associa-
tion studies (GWAS). While there is incredible utility in GWAS methods, extremely strong signals
are needed to overcome the multiple test corrections that occur when probing millions of different
SNPs. The effects of SNP variants in ADH and ALDH are so strong that they can be detected
in human GWAS studies, partially validating the theory that an individual’s genetics can predict
risk of AUD (Sun et al. 2019). As of 2019, tens of ethanol consumption-related genes have been
identified by GWAS and recent larger studies have produced > 10 relevant hits (Kranzler et al.
2019). Unfortunately, relatively few alcoholism-related genes that have achieved the threshold of
significance in further GWAS studies (Adkins et al. 2015). Since the pathophysiology of alcohol
dependence is considered polygenic, which many small changes in gene expression contribute to
the risk, detecting the individual genes is extremely difficult using traditional GWAS approaches
that require very strict statistical thresholds for significance.
Ethanol is known to interact with many different neural transmission receptor systems. In
brief, ethanol potentiates the following receptors: GABA-A, 5-HT3, neuronal nACh, GIRK chan-
nels, and glycine receptors (Belknap et al. 2008). In contrast, ethanol inhibits NMDA receptors and
voltage-gated L-type receptors (Belknap et al. 2008). While the direct actions on select individual
receptors are well studied, less is known about alcohol’s effect on cellular signaling, transporters,
or kinase cascades. We believe that unknown fundamental mechanisms for the pathophysiology
of alcohol lies in the sum of many modest effects of ethanol on multiple targets within important
pathways. In order to study and detect the small effects of many genes working in concert, genetic
researchers of complex traits, including mental illness and drug abuse, are utilizing network-based
analyses of genome-wide expression studies (e.g. microarray and RNAseq) to find organized net-
works of genes that are correlated by their expression and are also correlated, at a network level
with phenotypes of interest. This approach also allows functional analysis of multiple correlated
genes, using gene enrichment tools and pathway analysis of clusters of genes. Thus, groups of
genes with modest changes in expression can be identified and organized into functional domains
for hypothesis testing in relation to a given complex trait. This approach has led to the identifica-
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tion of many important clusters of co-expressed genes, giving more insight into important signal
cascades and pathways, such as the PI3K/AKT pathway that will be discussed later in this chapter,
that are simply not detectable with GWAS methods alone due to the very large samples sizes that
are needed to detect genes having small contributions toward a trait such as AUD.
2.3 Myelin as a risk factor
There is growing interest in studying and identifying genes and mechanisms that contribute to
impulsivity in alcoholics due to the clear direct link between impulsivity and AUD, where alcohol
dependent subjects have increased levels of impulsivity (Sun et al. 2019). Sun and company con-
cluded that effects of alcohol abuse related variants that affect impulsivity should be considered
an important area of future research. It is well documented that as the adolescent brain matures,
there are large increases in myelination in the frontal cortex (Sharma et al. 2013). During this tran-
sition, reduced myelination in the prefrontal cortex is correlated with deficits in compulsivity and
impulsivity in adulthood (Ziegler et al. 2019). In particular, Ziegler et al. found that myelination in
the dorsomedial and dorsolateral PFC regions are important for compulsivity, while the lateral and
medial PFC regions are important for impulsivity. Thorough reviews of addiction literature clarify
that both impulsivity and conpulsivity are contributors to development of addictions (i.e., drugs of
abuse, gambling), including alcohol, rather than being the result of the addiction behaviors (Lee,
Hoppenbrouwers, and Franken 2019).
As alluded to in Chapter 1, multiple molecular, pathological and neuroimaging studies show
perturbation of myelin or myelin gene expression in alcoholic patients. This has been shown in
postmortem human tissue, functional imaging studies, and in multiple animal models. Early stud-
ies using two commonly used inbred strains of mice, C57BL/6J (B6) and DBA/2J (D2), demon-
strated strikingly different behavioral responses to acute ethanol exposure and ethanol consump-
tion. For example, B6 mice drink much more ethanol than D2 mice, while D2 mice display much
larger locomotor responses to acute exposure (Phillips et al. 1994; Metten et al. 1998). Prior
genomic studies from our laboratory suggested possible mechanisms responsible for these differ-
ences in acute ethanol sensitivity between B6 and D2 mice (Kerns et al. 2005). K-means clustering
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analysis identified a group of genes in the medial prefrontal cortex (mPFC) which contained mul-
tiple myelin-related genes. This cluster of genes showed higher basal expression in B6 mice, but
demonstrated a greater degree of gene expression induction after acute ethanol exposure in D2
mice (Kerns et al. 2005). Genomic studies of Fyn kinase null mice also provided evidence that
alterations in myelin expression underlies the increased ethanol sensitivity, as demonstrated by
prolonged LORR duration in the Fyn-null mice (Farris and Miles 2013). Additional works by Far-
ris et al. found that administration of a demyelinating drug, Cuprizone, resulted in dramatically
reduced basal expression of myelin genes in the mPFC of B6 mice, increased LORR duration, and
decreased ethanol consumption and preference in a 2-bottle choice drinking model (unpublished
data / Farris thesis).
Therefore, it stands that basal levels of myelin and networks of myelin related genes in the
prefrontal cortex in particularly important for behavioral deficits that raise the risk of developing
alcohol dependence. We previously discussed how both myelin density and gene expression is
markedly downregulated in in the PFC of chronic alcoholic patients (Lewohl et al. 2000). Thus,
the regulation of myelin related genes is paramount for both the risk of developing abusive alcohol
behaviors and, as will be discussed, chronic ethanol abuse leads to later dysregulation of myelin
genes. This dysregulation of myelin genes then contributes to further escalations in abusive behav-
iors and drives the pathophysiology of cognitive deficits and brain matter loss following years of
alcohol abuse. To summarize, we hypothesize that basal expression of myelin related genes in the
prefrontal cortex can function as risk factors for AUD by altering initial sensitivity to ethanol (e.g.
impulsivity and compulsivity). Additionally, the dysregulation of myelin related gene expression
following chronic ethanol exposure also affects the risk of developing an AUD and contributes
to the neurological sequelae that result from years of abuse (see Figure 2.1). Given the potential
importance of myelin genes for the pathophysiology driving the development of AUD, studies on
ethanol regulation of myelin-related gene expression networks could be of critical importance to
the alcohol research field.
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Figure 2.1: Role of myelin in development of alcohol dependence. Figure from: Costin and Miles
2014.
2.4 N-myc Downstream Regulated Gene 1
As described above, Kerns and company found clusters of co-expressed genes when comparing
basal and differential gene expression changes in response to acute alcohol in D2 and B6 mice
(Kerns et al. 2005). One of the clusters of genes in the mPFC was highly enriched for myelin related
genes, as shown is Figure 2.2. Within this cluster, a novel ethanol responsive, myelin-related gene,
N-myc Downstream Regulated Gene 1 (Ndrg1), was identified.
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Figure 2.2: Cluster of myelin related ethanol responsive genes in the mPFC. Microarray probesets
for Ndrg1 are highlighted in red. Figure adapted from: Kerns et al. 2005.
2.4.1 General background
NDRG1 is part of the N-myc downregulated gene (NDRG) family, which contains 4 NDRG
proteins. All family members belong to the alpha/beta hydrolase superfamily. In humans, the
NDRG1 protein is 53% homologous to NDRG2 and 62% homologous to both NDRG3 and NDRG4
(Sun et al. 2013). Furthermore, human NDRG1 is 94% homologous to the mouse homolog, and
the NDRG1 sequence is highly conserved in many other organisms (Sun et al. 2013). Relative to
other members of the NDRG family, NDRG1 has a unique 10 amino acid that repeat 3 times in
tandem near the C-terminus, as shown in Figure 2.3 (Murray et al. 2004). The NDRG1 protein
is typically found in the cytoplasm of many different cell types and it is thought to be involved
in cellular stress responses, cancer related signaling pathways, and cell trafficking, particularly in
myelin-producing cells (Berger et al. 2004). For example, Ndrg1 is required for cells to undergo
p53-induced apoptosis (Stein et al. 2004), by playing a role in p53-mediated checkpoint at the mi-
totic spindle (Kim et al. 2004). There is evidence that other acute cellular stresses, such as hypoxia,
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can result in dramatic increases in Ndrg1 mRNA expression and protein phosphorylation over a
24-hour window of observation in tumor cell lines (Sibold et al. 2007). While the exact function of
NDRG still remains unknown, several studies have suggested that phosphorylation of the protein
affects its functional roles (Sun et al. 2013).
2.4.2 The Role of Sgk1-Mediated Phosphorylation
NDRG1 has been identified as substrates for phosphorylation by two important serine/threonine
kinases, Serum/Glucocorticoid Regulated Kinase 1 (SGK1) and Glycogen Synthase Kinase 3 Beta
(GSK3B) (Murray et al. 2004). The authors found that NDRG1 is phosphorylated on several
residues in the 10 amino acid tandem repeat near the C-terminus, as shown in Figure 2.3. Further-
more, initial phosphorylation of the SGK1 targets primes the protein for additional phosphorylation
by GSK3B (Murray et al. 2004). Furthermore, initial phosphorylation of the SGK1 targets primes
the protein for additional phosphorylation by GSK3B (Murray et al. 2004). When phosphorylated
at the thr-346 residue, NDRG1 colocalizes with γ-tubulin on centromeres during mitosis and with
microtubule bundles at late in the telophase stage in HCT116 cells (McCaig et al. 2011). Interest-
ingly, this phosphorylated NDRG1 does not localize with centromeres at all during the cell growth
phase (McCaig et al. 2011). Recently, investigations of Ndrg1 in the peripheral nervous system
also have noted that a reversible phosphorylation of the thr-346 residue determines the subcellular
localization of the protein in Schwann cells (Skedsmo et al. 2019). The authors suggest that sig-
naling cascades responsible for the phosphorylation event are important for the regulation of the
subcellular location of Ndrg1 in myelinating cells (Skedsmo et al. 2019). In specific, the authors
note that thr346-NDRG1 is only present in the abaxonal cytoplasm of Schwann cells (Skedsmo
et al. 2019). Based on the literature, there appear to be multiple mechanisms that control the
subcellular localization of NDRG1 beyond phosphorylation. For instance, in human trophoblasts,
cellular stressors result in a redistribution of NDRG1 into the nucleus and to areas of the cytoplasm
involved with endoplasmic reticulum and microtubule functions (Shi et al. 2013).
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Figure 2.3: NDRG1 protein domains and binding sites. Note the residues phosphorylated by
SGK1 and GSK3B near the C-terminus. The phospho-sites within the 3 tandem repeat are unique
to Ndrg1. Figure adapted from: http://atlasgeneticsoncology.org/
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Interestingly, this redistribution of NDRG1 is ameliorated if the phosphopantetheine attach-
ment site (see Figure 2.3) contains loss of function mutations (Shi et al. 2013). The evidence
suggests that multiple domains of the NDRG1 protein are involved in determining the sub-cellular
localization of NDRG1, and that the driving mechanism is determined by the cell type.
2.4.3 Ndrg1: importance in lipid dynamics and myelination
As stated in Chapter 1, mutations involving Ndrg1 in humans underlie Charcot-Marie-Tooth
disease type 4D, an autosomal recessive demyelinating peripheral neuropathy that results in widespread
demyelination and the appearance of onion bulb formations when viewing the cross sections of
myelinated axons (King et al. 2011). More extensive immunohistochemistry studies of the NDRG
family found high levels of NDRG1 expression in areas enriched with myelin, with little to no
expression outside of myelin or the myelinating cells of the nervous system (Okuda, Kokame, and
Miyata 2008). Constitutive deletion of Ndrg1 in mice results in degradation of peripheral myelin
starting at week 5 that progresses into a severe polyneuropathy (Okuda et al. 2004). As mentioned
above, thr346-pNDRG1 is only present in the abaxonal cytoplasm of Schwann cells in healthy
control dogs. Alaskan malamutes, a breed with known Ndrg1-induced neuropathies, with defec-
tive Ndrg1 lack this phosphorylation event (Skedsmo et al. 2019). While phosphorylation and
cellular sub localization of NDRG1 is certainly important, reviewing the literature suggests that
Ndrg1-induced neuropathies are largely due to Ndrg1’s effects on cellular lipid dynamics. Studies
have shown that patients with defects in NDRG1 frequently developed hypercholesterolemia and
defects in reversed transport of cholesterol in addition to the neuropathy symptoms (Dacković et al.
2008). It has been shown that NDRG1 co-localizes and directly interacts with apolipoproteins,
APO-AI and A-II, which suggests that the lack of functional NDRG1 in Schwann cells, and the
resulting defects in lipid synthesis, transport, and trafficking, are the major driver of the pathology
observed in CMT4D (Hunter et al. 2005). It was later determined that knocking down expression
of NDRG1 in epithelial cells reduces the cell surface density of LDL receptors, resulting in re-
duced uptake of LDL (Pietiäinen et al. 2013). The authors also knocked down NDRG1 in rodent
oligodendrocytes and found similar reductions in cellular uptake of LDL and reduced expression of
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the oligodendrocyte differentiation factor, Olig2 (Pietiäinen et al. 2013). The authors determined
that NDRG1 modulates the formation of multivesicular bodies and LDL receptor trafficking, and
they ultimately conclude that part of the pathophysiology of CMT4D can be attributed to impaired
control of cellular lipid dynamics, since functional Ndrg1 is required for proper myelination in the
PNS due to its role in biolipid synthesis and transport, and through reductions in differentiation
signals in myelinating cells (Pietiäinen et al. 2013). The importance of NDRG1 in cellular lipid
dynamics is not restricted to myelinating cells. Ndrg1 expression levels in breast cancer cells affect
the aggressiveness of cells by altering the cell’s lipid profile (Sevinsky et al. 2018). The authors
found that Ndrg1 expression modulates both the cellular uptake of lipids, by affecting how neutral
lipids store fatty acids, and endogenous cellular lipid biosynthesis (Sevinsky et al. 2018). Multiple
works have provided evidence that NDRG1 directly interacts with both E-cadherin and B-catenin,
and these interactions suggest the role of Ndrg1 in cancer metastasis and aggressiveness may be
in part to modulations in the epithelial-to-mesenchymal transition (EMT) that are mediated by the
Wnt pathway (Tu et al. 2007; Liu et al. 2012; Jin et al. 2014; Cen et al. 2017). The evidence
suggests that at least part of NDRG1’s effects on lipid metabolism are mediated through the Wnt
signaling cascade, given that the Wnt pathway has recently been implicated in altering the lipid
metabolism profile in the hepatocytes of zebrafish following toxic insults and injuries (Yao et al.
2018).
2.5 Ndrg1 and chemotherapy-induced peripheral neuropathy (CIPN)
One of the most important chemotheraputics used in the treatment of breast of cancer is Pa-
clitaxel (Perez 1998). Paclitaxel is considered a first-line treatment for metastatic breast cancer,
as an adjuvant treatment following surgery, and for anthracycline-resistant cancer (Perez 1998).
Paclitaxel is a member of the taxane family, a class of drugs that have antimicrotubule functions.
Paclitaxel is distinguished from others taxanes in that it indirectly prevents depolymerization of
microtubules by inducing tubulin dimerization (Rowinsky, Cazenave, and Donehower 1990). As
noted by Rowinsky, Cazenave, and Donehower 1990, the two common toxicity side effects of Pa-
clitaxel are neutropenia and peripheral neuropathy. While many agents lead to chemotherapy in-
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duced peripheral neuropathy (CIPN), Paclitaxel is one of the few that causes symptoms both while
undergoing treatment or immediately following treatment (Zajaczkowska̧ et al. 2019). While CIPN
is a sensory and a motor neuropathy, the first symptoms to appear are sensory and occur in the dis-
tal ends of limbs, which results in “stocking and glove” complaints in the feet and the hands,
respectively (Zajaczkowska̧ et al. 2019). Given that CIPN can result in permanent neuropathic
symptoms that reduce quality of life following treatment, research to identify genetic variants that
modulate the risk and severity of CIPN is of critical clinical importance. A study investigating the
association of single nucleotide polymorphisms with CIPN in an Asian population found that an
NDRG1 SNP, rs2233335, correlated with Paclitaxel induced peripheral neuropathy (PIPN) (Sun-
dar et al. 2014). Furthermore, they found that additional NDRG1 SNPs in linkage disequilibrium
with rs2233335 were localized to intronic regions, suggesting that some regulatory mechanisms
for the expression of NDRG1 may be driving the association of NDRG1 with PIPN (Sundar et al.
2014). This group followed up by investigating the levels of NDRG1 expression in nerve bundles
in the resected breast tissue following mastectomy or lumpectomy that includes the nipple (Sundar
et al. 2016). Following surgery, all women received up to 12 cycles of weekly Paclitaxel unless
toxicity developed. The authors found a strong inverse correlation of the amount of nerve Ndrg1
expression and severity of CIPN symptoms experienced by the patients (Sundar et al. 2016). While
the authors acknowledge that performing nerve biopsies for predicting sensitivity to and severity
of CIPN is not practical, they provide evidence that investigating nerve bundles within resected
tumor tissue could be a useful biomarker for predicting severity of PIPN (Sundar et al. 2016).
2.6 Ndrg1: involvement with signaling pathways
Even though is no reported detectable NDRG1 in axons or neurons, NDRG1-related neu-
ropathies in humans, rodents, and dogs all have clinical signs and pathological evidence that imply
an axonal neuropathy (Skedsmo et al. 2019). In the peripheral nervous system, axonal Neuregulin1
acts on the PI3K/AKT pathway such that NDRG1 protein levels are upregulated, and an induction
of myelination follows (Heller et al. 2014). In contrast, a later interaction of axonal α6β4 integrin
results in Sgk1 activation in the Schwann cells, inducing thr-346 phosphorylation of NDRG1 at the
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Cajal bands within the abaxonal compartments, which results in down-regulation of myelination
(Heller et al. 2014). This work demonstrates that axonal-glial junction cross-talk regulates the in-
duction and reduction of myelination by acting through differing parts of the PI3K/AKT pathway.
The theory is supported by the fact that many different cell types have the PI3K/AKT pathway
activated by the binding of ligands to various integrins located on the cell surface (Matsuoka et al.
2012).
It has been shown that the PI3K/AKT signaling pathway in involved in alcohol pathology,
in multiple organ systems. One study found that low dose and high dose acute alcohol exposure
in cardiac myocytes had opposing effects on cardiac output, and constitutively active or inhib-
ited PI3K either blocks or enhances the effects on cardiac function (Umoh et al. 2014). The
authors suggested that cardiac response to acute alcohol is driven by the effects of the pathway
on oxidative stress (Umoh et al. 2014). Additionally, it is known that alcohol-related liver disease
(ARLD) is driven in large part by oxidative stress (Liu et al. 2019). ARLD is responsible for many
cognitive issues, especially in the frontal cortex (Zahr and Pfefferbaum 2017). Within the CNS,
PI3K/AKT pathway plays an important role in modulating maladaptive alcohol behaviors via the
mesocorticolimbic circuity. Initial studies found that the mammalian target of rapamycin complex
1 (mTORC1) signaling pathway is activated in the nucleus accumbens (NAc) after ethanol expo-
sure (Neasta et al. 2010). Since AKT is the primary upstream activator of the mTORC1 pathway,
the authors followed up and found that the AKT pathway is activated in the NAc of rats following
an alcohol paradigm involving multiple cycles of excessive consumption and withdrawal (Neasta
et al. 2011). Furthermore, the authors found that intra-NAc delivery of an inhibitor for either AKT
or its activator, PI3K, reduces the excessive voluntary consumption and operant responding for
alcohol (Neasta et al. 2011). These examples show that perturbations of the PI3K/AKT pathway
can play a large role in CNS responses to ethanol, especially in the acute setting.
Additionally, the Wnt/B-cantenin pathway has been implicated in CNS responses to ethanol
exposure, especially in the context of acute tolerance. In fact, the rapid acute function tolerance,
both molecular and behavioral, is thought to be mediated by the internalization of large conduc-
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tance Ca2+ and voltage-activated K+ (BK) channels (Treistman and Martin 2009). The inter-
nalization of the BK channels, and the rapid tolerance to acute ethanol that follows, occurs on
the scale of minutes after the initial exposure to ethanol (Treistman and Martin 2009). Further-
more, this mechanism is conserved across multiple species and animal models, which suggests that
this is a fundamental regulator of tolerance to the effects of ethanol and the increased consump-
tion and preference that follows (Bettinger and Davies 2014). In relation to the Wnt/B-cantenin
pathway, studies in cultures of hippocampal neurons suggest that the Wnt pathway regulates the
ethanol-induced internalization of BK channels by phosphorylation of the channel by GSK3B,
which drives the development of acute tolerance to ethanol (Velázquez-Marrero et al. 2016). Fur-
thermore, Treistman et al. 2009 suggests that lipid environment of the cell membrane in the vicinity
of the BK channel is a strong modulator of effects of ethanol on the channels. It has been shown
that the activation of BK channels by ethanol is affected by the cholesterol/phospholipid ratio of
the cell’s lipid bilayer (Crowley, Treistman, and Dopico 2003). In addition, studies have found
that the cell’s bilipid membrane thickness modulates to response of BK channels to ethanol: BK
channels in thinner membranes have stronger responses to ethanol, while response of BK channels
in thicker membranes is blunted (Yuan et al. 2007). BK channels, such as KCNMA1, have been
directly observed on the surface of axons and the synaptic terminals of glutamatergic connections
in the hippocampus and the GABAergic connections in the cerebellum (Misonou et al. 2006). Also
of note, BK channels are concentrated at the paranodal junctions of myelinated axons in Purkinje
cells, where they help regulate action potentials (Hirono et al. 2015). Given that NDRG1 is also a
member of the Wnt signaling pathway that is responsive to axon-glial cross-talk, and it is known
modulate to lipid and cholesterol uptake and metabolism. It is possible that the main effect that
NDRG1 may have on acute sensitivity may be mediated through Wnt signaling and alterations in
the lipid composition along the axon-glial junction.
Probing the BioGrid repository for mass-spec affinity captured, protein-protein interactions of
NDRG1 reveals that the top interaction with the most evidence is with KCNMA1 (Kathiresan et al.
2009). The NDRG1-KCNMA1 interaction came out of a publication on the protein-protein net-
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work for Kcnma1 in mouse cochlea, which is a transition zone of the PNS and the CNS (Kathiresan
et al. 2009). 161 unique protein interactions with KCNMA1 were identified in this study. Running
this list of genes through Toppgene reveals several interesting GO enrichment categories. Notably,
cellular component GO results include: myelin sheath, synapse, secretory vesicle, supramolecular
fiber, microtubule, and endocytic vesicle. GO results for mouse phenotype also includes myelin
and axon related pathologies, such as: axon degeneration, abnormal metabolism, abnormal tricar-
boxylic acid cycle, hindlimb paralysis, abnormal myelination, and abnormal action potential. Even
more striking are the human phenotype GO results, which include: segmental peripheral demyeli-
nation/remyelination, spastic paraplegia, onion bulb formation, abnormality of the cerebral sub-
cortex, Abnormal corpus callosum morphology, Hypertrophic nerve changes, Aplasia/Hypoplasia
of the corpus callosum, Abnormality of peripheral nerve conduction, Abnormality of the cerebral
white matter, abnormality of peripheral nerves, and peripheral axonal degeneration
These GO results, along with the 161 protein-protein interactions, suggest that KCNMA1
along the axon directly interacts with myelin and/or lipid-related proteins, such as MBP, MPZ,
APOA1, APOE, and NDRG1. This raises the possibility that NDRG1 could modulate acute tol-
erance and sensitivity to ethanol through the axon-glial cross-talk, perhaps by altering the lipid
composition at the axon-glial junction, which then modulates the magnitude of action potential
and the rate of internalization the KCNMA1 channel.
2.6.1 Ndrg1 is an upstream regulator and a downstream target of ethanol responsive sig-
naling pathways
As discussed above, Ndrg1 plays an important role in at least 2 ethanol-responsive signal path-
ways: PI3K/AKT and Wnt/β -cantenin. A thorough review of Ndrg1 by Sun et al. 2013 demon-
strated that Ndrg1 has direct interactions with additional signaling cascades, including: TGF-β ,
Ras/Raf, and NF-κβ , as shown in Figure 2.4.
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Figure 2.4: Overview of NDRG1 interactions upstream of signaling pathways. Figure adapted
from: http://atlasgeneticsoncology.org/
It is thought that Ndrg1 acts on each pathway in an independently, but it might also pro-
mote cross-interactions (Sun et al. 2013). It has been reported that the actions of Ndrg1 on the
NF-kB pathway is dependent on SGK1-mediated phosphorylation of NDRG1 residues, Ser330
and Thr346 (Murakami et al. 2010). Ndrg1 plays a role in upstream inhibition of the PI3K/AKT
via NDRG1 activation of SMAD4 and PTEN. The relationship between PI3K/AKT pathway and
Ndrg1 is complex, as shown in Figure 2.5. In peripheral nerves, Ndrg1 is a downstream target of
the PI3K/AKT as it is phosphorylated by both Sgk1 and Akt1 (Heller et al. 2014). This demon-
strates that Ndrg1 has roles both upstream and downstream in the PI3K/AKT pathway, suggesting
a possible feedback role in regulation of this pathway.
2.7 Investigations of mPFC Ndrg1 and alcohol
To reiterate, both Sgk1 and Gsk3β , kinases that phosphorylate Ndrg1 as discussed above, are
members of the PI3K/AKT pathway and both have been found to be ethanol responsive kinases
in the mPFC of rodents following acute exposure (Kerns et al. 2005; Wolen et al. 2012; Costin,
Dever, and Miles 2013; van der Vaart et al. 2018). The regulation of Sgk1 in the mPFC of D2
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mice has been studied in greater detail in prior work in our laboratory (Costin, Dever, and Miles
2013). Costin and company found that acute ethanol leads to a dose-dependent upregulation of
Sgk1 mRNA expression 4 hours following exposure and increases the level of phosphorylated
SGK1 (Ser-422 and Thr-256) and phosphorylated NDRG1 (Ser330) 15 minutes after exposure
(Costin, Dever, and Miles 2013). This work provided evidence that acute ethanol does in fact
regulate the phosphorylation of NDRG1 in the mPFC, but it only provides a single time point, 15
mins after exposure, and a single dose (4 g/kg, i.p.). As discussed above, multiple previous studies
have demonstrated that phosphorylation of NDRG1 by SGK1 and GSK3B leads to changes in the
cellular sub-localization of NDRG1. Taken together, these works certainly suggest that cellular
stresses can lead to increased phosphorylation of NDRG1 and subsequent changes in NDRG1
sub-cellular localization, potentially altering the activity and physiological function of the protein.
At this time, there have been no studies concerning the effect of chronic ethanol exposure on Ndrg1
expression and protein phosphorylation. This information could elucidate whether or not Ndrg1
plays a role in the alterations in mPFC-mediated neurobiology that leads to myelin alterations
and lead to addictive behaviors following chronic exposure to ethanol. Bioinformatic analysis
of mPFC expression data found that Ndrg1 expression was positively correlated with voluntary
ethanol intake across the BXD panel of mice and demonstrated that the basal levels of Ndrg1
mRNA expression in the mPFC across seven different strains of mice was inversely correlated
with LORR duration time, as shown in Figure 2.5.
Additionally, in unpublished data from the Miles laboratory, modulation of mPFC Ndrg1 was
achieved via stereotaxic injection of lentivirus containing shRNA that targets the Ndrg1 transcript.
This site-specific knock down of Ndrg1 in the mPFC produced alterations in ethanol phenotypes
that are related to ethanol sensitivity. First, the knock down mice experienced prolonged LORR du-
ration relative to scrambled shRNA controls. Interestingly, after 4 weeks of intermittent access to a
3-bottle choice drinking model (15%, 30%, water), NDRG1 knock-down mice showed a markedly
decreased preference for the 30% ethanol relative to the 15% ethanol, as displayed in Figure 2.6,
while overall ethanol consumption was unchanged between the control and the knockdown ani-
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mals. We have postulated that the knockdown animal’s decreased preference for 30% is due to an
altered sensitivity to the intoxicating or adverse effects of the higher concentration of ethanol.
Figure 2.5: Basal NDRG1 expression is inversely correlated to LORR duration across 7 different
laboratory mice strains (left). Correlation of alcohol consumption with NDRG1 basal expression
across the panel of BXD mice (right). Figures adapted from Farris thesis / unpublished manuscript.
Figure 2.6: Ethanol phenotypes from shRNA knockdown of NDRG1 in the mPFC of B6 mices.
The knockdown mice display significantly longer LORR durations (left). Knockdown mice (red)
reduced their intake of 30% relative to 15% ethanol the course of the drinking study, while scramble
injected controls (black) escalated their consumption of 30% over the 15% ethanol (right). (* P <
0.05). Figures adapted from: Farris thesis / manuscript in preparation.
2.8 Closing Remarks
The works discussed in this chapter suggest that basal myelin expression is an important de-
terminant of acute sensitivity to ethanol and hence, to the risk for abusive ethanol consumption.
They further document that ethanol can regulate myelin expression in the mPFC and that Ndrg1
is a potential key gene involved in this response. We hypothesize that Ndrg1 expression is an
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important factor determining sensitivity to ethanol and that regulation of Ndrg1 by ethanol may
have a role in the long term risk for abusive consumption. Furthermore, given the direct role of
Ndrg1 in peripheral neuropathies and suggested role in severity of chemotherapy-induced periph-
eral neuropathy, we hypothesize the sensitivity for the development of alcoholic neuropathy may
modulated by Ndrg1 expression in the Schwann cells of the peripheral nervous system.
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Chapter 3
Characterization of cellular expression and ethanol
regulation of Ndrg1 in the mPFC
3.1 Introduction
Ndrg1 expression is induced and is strongly correlated with a cluster of myelin-related genes
in the mPFC of male D2 mice 4 hours after acute ethanol (2 g/kg, ip) (Kerns et al. 2005). A
significant increase of Ser330-pNDRG1 levels occurs in the mPFC of male D2 mice 15 minutes
after a large dose of acute ethanol (4 g/kg, ip) (Kerns et al. 2005). Ndrg1 expression was mod-
ulated in rhesus macaques mPFC following 1 year of chronic ethanol consumption (Bogenpohl
et al. 2019). Network analysis found that Ndrg1 was a member of network that was enriched for
myelin-related genes and that Ndrg1’s connectivity within this module is dramatically increased in
rhesus macaques that underwent the year of drinking (Bogenpohl et al. 2019).
The sub-cellular localization of Ndrg1 is affected by it’s phosphorylation state at Sgk1-mediated
residues in multiple cell cancer lines (Park et al. 2018). However, other works have reported no
changes in sub-cellular localization based on the phosphorylation state in Hela cells (Murray et al.
2004). It is thought that the phosphorylation of Ndrg1 at Sgk1-mediated residues is important for
the function of the NDRG1 protein (Murray et al. 2004). It was not known if oligodendrocytes
in the CNS would demonstrate sub-cellular localization of NDRG1 based on its phosphorylation
state. Furthermore, it was also unknown if either acute or chronic ethanol would induce changes
in the levels or the sub-cellular localization of phospho-NDRG1 in the CNS. If the phosphoryla-
tion state of Ndrg1 does in fact play a role in protein function, it would be a vital addition to the
current knowledge base of Ndrg1 expression in the CNS, both basally and in the context of acute
and chronic ethanol exposure.
26
The previous findings regarding Ndrg1 in mouse models were generated in the D2 strain. It
is advantageous to investigate this further using the reference B6J mouse strain. This is espe-
cially important since we plan to modulate the expression of Ndrg1 through genetic interventions
in Chapter 4, as nearly all existing genetically modified mouse lines are created on a B6J back-
ground. Furthermore and even more importantly, D2 mice are known to consume significantly less
ethanol per body weight than B6J mice due to alterations in taste perception. Given that we plan
to use a genetically modified mouse line and we plan to study drinking behaviors in the context of
Ndrg1, we utilized mouse lines bred over a B6J-reference background for all studies throughout
this dissertation. As such, this thesis work will add vitally important data on the regulation of
Ndrg1 following both acute and chronic ethanol exposure in reference mouse strain, B6J.
Outside of the preliminary lentiviral data discussed in Chapter 2, there are no reports or studies
published concerning the effect of chronic ethanol exposure on Ndrg1 expression in any organ sys-
tem. We will begin our investigation by determined the predominant cell type that is infected by
the lentivirus in this preliminary study using immunofluorescence methods. We will then further
test to see if the predominantly infected cell type is localizes with NDRG1 protein to determine if
Ndrg1 is in fact expressed in this cell type. It is entirely unknown what effects long-term ethanol
exposure with have on the transcript expression or proteomics dynamics for Ndrg1. It is also
unknown if any changes in Ndrg1 phosphorylation following acute ethanol are also observed fol-
lowing chronic ethanol drinking. In other words, mice repeatedly exposed to ethanol that escalate
their voluntary usage could have enhanced, diminished, or no change in ethanol-induced phospho-
rylation of NDRG1compared to naive mice that received an equivalent ethanol dose. This could
be crucial to providing information on how the response of Ndrg1 may adapt after acute exposures
turns into chronic usage. As eluded to in Chapter 2, any compensations in response to ethanol
exposure could play a vital role in the development of the pathophysiology behind maladaptive
alcohol usage.
To establish the basal expression patterns of Ndrg1 in the mPFC, we will use immunofluores-
cence methods to determine the cell type localization of total NDRG1 protein. We will also use
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IHC to determine the sub-cellular localization of multiple phosphorylated forms of NDRG1 pro-
tein in the mPFC of B6J mice. To characterize to the effect of acute ethanol on Ndrg1expression
or protein activity of NDRG1, we utilize an acute ethanol dose response model with 4 different
doses administered via intraperitoneal injection. Additionally, sub-cellular localization of 2 forms
of phosphorylated NDRG1 (Ser330-pNDRG1 and Thr346-pNDRG1) will be investigated follow-
ing a single dose of ethanol in a smaller subset of male mice using super resolution microscopy
techniques
Likewise, we sought to determine the effects of chronic ethanol on the gene expression and
protein activity of Ndrg1 by establishing an escalating alcohol consumption using an Intermittent
Ethanol Access (IEA) model. We will track and compare the amount of ethanol relative to tap
water consumed both 2 hours into the session (binge-like behavior) to the 24 hour measurements
at the end of session. We will compare consumption and preference for male and female B6J mice.
In addition, we will confirm the binge-like alcohol consumption by determining the blood ethanol
content (BEC) at the 2 hour mark in a smaller subset of the mice in the drinking study. And finally,
since Ndrg1 expression is known to be co-expressed and correlated with other myelin related genes
in the mPFC (Kerns et al. 2005; Bogenpohl et al. 2019), we will also determine protein or transcript
alterations of myelin genes following both the acute and the chronic ethanol models.
3.2 Materials and Methods
3.2.1 Animals
For all experiments conducted in this Chapter, C57BL/6J mice of both genders were ordered
from Jackson laboratories (Bar Harbor, Maine) and delivered at 8 weeks of age. All mice were
housed in a temperature vivarium space that was set to a 12 hour light cycle. At 9 weeks of age,
the mice utilized for drinking studies were habituated to housing in a different out of vivarium
(OOV) space for 1 week prior to the beginning of drinking. The mice in the OOV space were
singly housed in open air cages on SaniChip wood chip-based bedding. For the acute ethanol
studies, mice remained group housed (N=3 or 4 per cage) on corn cob-based bedding the vivarium
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for the duration of the studies. Habituation to acute intraperitoneal injections began at 10 weeks
of age. The group housed mice were maintained in static rack-mounted cages with active air
circulation. All cages were changed once a week for the duration of the studies. All mice had ab
libitum access to standard chow (Teklad food pellets, Envigo, Hungtingdon, UK) and tap water.
All procedures performed on the animals within our laboratory protocol, which was approved by
the VCU Institutional Animal Care and Use Committee and were compliant with the NIH Guide
for the Care and Use of Laboratory Animals. Unless noted otherwise, all experiments within this
chapter contained equal numbers off male and female mice. For the study that characterizes the
basal expression of NDRG1 in the mPFC, 3 male B6J of 12-weeks of age were used.
3.2.2 Prepared Solutions
The injection solution for the IHC studies was either 0.9% normal saline or ethanol diluted
to 20% (v/v) in normal saline. The drinking solutions provided for the IEA study were either tap
water or ethanol diluted to 20% (v/v) in tap water. For the acute dose-response study, all ethanol
solutions were diluted to 18% (v/v) in normal saline. The formaldehyde solution (4% w/v) was
created by dissolving powdered para-formaldehyde into 0.9% saline using heat (65◦C) and by
adding 1N NaOH to bring the solution pH to 10. Once the para-formaldehyde powder was fully
dissolved under the described conditions, the solution was cooled and 1N HCL acid was added
drop wise to bring the formaldehyde solution to physiologic conditions (pH = 7.4).
3.2.3 Intermittent Alcohol Drinking
For studies on consumption with intermittent ethanol access (IEA), B6J mice (N=21/sex/group)
were transferred to an out-of-vivarium space, housed 1 animal/cage, and given one week to habit-
uate to the new environment. The mice were then provided access to 2 graduated glass conical
tubes with ball bearing sippers, and containing either 20% ethanol (v/v), diluted into tap water,
or plain unadulterated tap water. In brief, our protocol entailed providing 24-hour access to both
bottles within 1 hour of the beginning of the ’dark’ cycle on Monday, Wednesday, and Fridays.
Volume readings were marked as the bottles went on, 2 hours into the drinking sessions, and at the
24-hour time point when the bottles are removed after each session. For further details concerning
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the paradigm, consult Figure 3.1B. Drinking measurements were acquired for 5 weeks. 24 hours
following the final ethanol drinking session, chronic consumption mice were sacrificed by rapid
cervical dislocation and decapitation and harvested for tissue collection. Micro-dissection of the
individual brain regions was performed as previously described (Kerns et al. 2005).
3.2.4 Acute Ethanol Exposure
We used male and female B6 mice to determine the effect of acute ethanol on protein and
gene expression of Ndrg1. Following 3 days of habitation to saline injections, the mice were
intraperitoneally injected with one of the following doses of ethanol: 0.0 g/kg (saline control),
0.5 g/kg, 2.0 g/kg, and 4.0 g/kg. In all studies that utilized acute ethanol administration, mice
were habituated to injections all normal saline for the three days leading up to the experimental
injections (see Figure 3.1A). For the acute ethanol studies, the mice were sacrificed via cervical
dislocation at one of two time points. The animals utilized for protein studies (IHC, WB) were
sacrificed 30 minutes post-injection to detect phosphorylation state changes. The animals utilized
for transcript studies (qPCR) were sacrificed 4 hours post-injection, as previously described (Kerns
et al. 2005).
3.2.5 BEC Measurements
Near the conclusion of the drinking paradigm, blood was obtained for a subset of female and
male mice (N= 5 EtOH drinkers per sex, and N=1 water drinkers per sex) 2 hours following start
of the drinking session (see Figure 3.1B). Blood was extracted using the cheek punch method with
Goldenrod sterile lancets (Braintree Scientific, Braintree, MA), as previously described (Regan
et al. 2016). Blood was collected into EDTA-coated BD tubes (Fisher Scientific, Waltham, MA)
before it was spun down in a refrigerated centrifuge (4◦C) at 1500g for 15 minutes. The plasma
was extracted from the resulting supernatnate and stored at −80◦C until quantification. The mea-
surement of the blood ethanol content of the plasma was performed using an Analox AM1 alcohol
analyzer (Analox Instruments Ltd, UK) according to the manufacturer provided instructions. Of
note, of the male ethanol drinking samples could not be analyzed due to insufficient plasma col-
lection.
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Figure 3.1: Animal models of acute and chronic ethanol exposure. (A) Acute ethanol paradigms.
Left: acute dose response experiment. Right: acute IHC experiment. (B) Chronic ethanol
paradigm: Intermittent Ethanol Access (IEA) model. Left: Demonstrates the light schedule and
bottle schedule per week. Right: Details of the blood and tissue collection at the end of the drinking
study. Adapted from: Van der Vaart 2018
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3.2.6 Antibodies and Primers
Antibodies utilized for immunofluorescence studies:
Primary: anti-NDRG1 (1:500, Abcam, ab124689), anti-Thr346-pNDRG1 (1:400, Cell Sig-
naling Technology (CST), #3217), anti-Ser330-pNDR1 (1:400, Abcam, ab124713), anti-CNP
[11-5B] (1:400, Abcam, ab6319), anti-NeuN Antibody [A60] (1:500, Millipore, MAB377).
Secondary: AlexaFluor 488 anti-mouse IgG1 (1:1000, ThermoFisher, A-2112), AlexaFluor
568 anti-rabbit (1:500, ThermoFisher, A-11036)
Antibodies utilized for Western blotting studies:
Primary: anti-NDRG1 (1:1000, Abcam, ab124689), anti-Thr346-pNDRG1 (1:1000, Cell Sig-
naling Technology (CST), #3217), anti-Ser330-pNDRG1 (1:1000, Abcam, ab124713), anti-MBP
(1:1000, Abcam, ab7349), anti-GAPDH [6C5] (1:7500,Millipore, MAB374).
Secondary: 680LT Mouse IgG1 (1:50000; LiCor #926-68050), 800CW Rabbit (1:30000;
LiCor #926-32211), 800CW Rat (1:30000; LiCor #926-32219)
Genes targeted for qPCR analysis:
Ndrg1, Ublcp1, B2m, Mbp, Mag, Mobp, Mal.
The sequences for each primer pair used are provided in Table 3.1.
Gene Forward Reverse
Ndrg1 ATGAATGTGAACCCCTGTGC TATCTCCTCCTTGCCGAAGA
Ublcp1 ATCTCTCACCCTTGCCCTTT CCCATTTTGTGTGCTTTCGT
B2m GGAGAATGGGAAGCCGAACA TCTCGATCCCAGTAGACGGT
Mbp ACACACGAGAACTACCCATTATGG AGAAATGGACTACTGGGTTTTCATCT
Mobp AACTCCAAGCGTGAGATCGT CTCGGTCACTTCTTCCTTGG
Mal TCTTCACCACCTTCCCTGAC GCCACAAAGCAGAACACAGA
Table 3.1: Sequences for primers used in Chapter 3.
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3.2.7 qPCR Methodology
Total RNA was extracted from mPFC microdissected tissue using the RNeasy Mini Kit (Qia-
gen, #74104). RNA purity and concentration assessed by NanoDrop 2000 (ThermoFisher, ND-2000)
spectrophotometry and only samples with 260/280 ratios > 1.8 were analyzed further. cDNA was
synthesized using an iScript cDNA Synthesis Kit (BioRad, #1708891). PCR reactions were per-
formed using iQ SYBR Green Supermix (BioRad,#1708880) reagent and and a CFX Connect
Thermocycler (BioRad). Normalized expression values were calculated with the delta-delta Ct
method, where non ethanol-responsive genes, Ublcp1 and B2m, were used as reference genes.
Tukey’s HSD post-hoc testing was utilized for analysis of acute exposure data, while unpaired
Student’s t-test were applied for the chronic ethanol exposure data.
3.2.8 Western Blot Methodology
For all western blot studies in this chapter, tissue homogenization was performed using 1X
RIPA lysis buffer (50 mM Tris, 150 nM NaCl, 1% NP40, 5 mM EDTA, and 0.5% SDS). Microdis-
sected tissue was homogenized using 2 to 4 short pulses with an ultrasonic sonicator over ice.
To prevent protease and phospatase activity in the homogenized samples, 100X HALT Protease
and Phosphatase Inhibitor Cocktail (ThermoFisher, #78440) was diluted to 1X in all RIPA buffers
prior to homogenization. The homogenized solutions were partitioned into aliquots and imme-
diately frozen at −80◦C. Total protein concentration was determined by utilizing a Pierce BCA
Protein Assay Kit (ThermoFisher, #23225), to allow for equal protein loading. Before performing
an immunoblot, the proteins in the homogenized samples were denatured by heating the sample
dissolved in NuPage Reducing Agent (ThermoFisher, NP0004) and 4X Protein Sample Load-
ing Buffer (LiCor, #928-40004) in a heat block for 10 minutes at 70◦C. Both the electrophoresis
and the transfer steps were performed using the Xcell Surelock Mini Cell System (ThermoFisher,
EI0001). The denatured protein samples were loaded into NuPage 4-12% Bis-Tris 17-well gels
(ThermoFisher, NP0329BOX). Once equal amounts of total protein are loaded onto the gel, the
proteins are first separated by size using electrophoresis at 100V. The size separated gels were then
transferred onto Immobilon-FL PVDF Membrane (Millipore, IPFL00005) by applying 12V at 4C
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for 16 hours using NuPage Transfer Buffer (ThermoFisher, NP0006). Following transfer, the mem-
branes were briefly rinsed in milliQ water and were air dried for at least 1 hour to promote perma-
nent binding of transferred proteins. The membranes were then re-hydrated using 100% methanol
and rinsed with milliQ water. The membranes were then blocked in Licor Intercept Blocking
Buffer (Licor, #927-60001) for 1 hour before the immediate application of primary antibodies,
diluted in 1X blocking buffer containing .2% Tween-20. The primary antibodies were incubated
overnight at 4C before the solution is washed 4 times with 1X TBS with 0.1% Tween-20. The
membranes were then incubated with secondary antibodies were diluted into 1X blocking buffer
with 0.2% Tween-20, and then applied for 1 hour at room temperature. The membranes were then
washed 4 times with 1X TBS with 0.1% Tween-20, followed by rinses in 1X TBS to remove the
residual tween-20 from the washes. The membranes were stored submerged in 1X TBS in the dark
at 4C until ready to image. Imaging was performed using the Odyssey Infrared Imaging System
(Licor, #9120). The experimental proteins were stained using the species-specific 800CW sec-
ondary at 1:30,000 dilution. The loading control and normalization protein, GAPDH, was stained
using the 680LT anti-mouse antibody specific to mouse IgG1 at a concentration of 1:50,000. All
scans were analyzed and quantified using the FiJi image analysis software package (ImageJ, NIH).
Because the membrane was thoroughly dried following transfer, the membranes can be safely
stripped of the primary/secondary antibodies multiple times without noticeable protein loss. The
stripping of the membranes was performed using 1X NewBlot IR Stripping Buffer (Licor, #928-40028)
for 20 minutes with vigorous shaking, followed by multiple wash steps. A new aliquot of the sec-
ondary antibody staining solution is then incubated on the stripped membrane and re-imaged to
determine efficacy of the stripping of the signal. Using this methodology, we were able to measure
both phospho-forms of NDRG1, total NDRG1, and myelin related genes using a single membrane
in most cases.
3.2.9 Immunohistochemistry Methodology
All mice were perfused with transcardial administration of a 4% formaldehyde solution (in
1X PBS) while anesthetized with high doses of isoflurane. The mice were first flushed with pure
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1X PBS to remove the remaining blood before the 4% formaldehyde was injected. The perfused
brains were then removed from the skull and transferred to a vial of fresh 4% formaldehyde for an
overnight post-fixation step. The brains are then placed into a 30% sucrose solution dissolved in
1X PBS for dehydration of the remaining water. Once the brains were fully dehydrated and sunk
to the bottom of the sugar solution, they were snap frozen in a vial of isopentane that was cooled
to -80C using dry ice and then stored at -80C until they are ready to proceed. The frozen brains
are then cut into 20um thick coronal sections using a Leica CM3050 cryostat (Leica Biosystmes,
Wetzlar, Germany). The sliced sections stored as free-floating sections that were submerged in a
1X PBS solution containing 0.02% sodium azide to preserve and prevent bacterial growth. The
slices were stored in order along the wells of a 24-well plate.
Prior to staining of the coronal slices, the antigens that are masked by protein cross linking
are recovered by placing the slices in Citrate Acid Buffer (pH = 6.0) and heating at 80C for 20
minutes with shaking, followed by a 30 minute cool-down step at room temperature with vigorous
shaking. Following this antigen retrieval process, the sections are then permabolized and blocked
in 10% goat serum with 0.2% Triton X100 for 30 minutes are room temperature. The sections
were then incubated overnight at 4C with primary antibodies that are dissolved in 1XPBS with
0.2% Triton-X with gentle rocking. The slices are then washed 4 times in an abundance of 1X PBS
for 5 minutes with vigorous shaking. Following the fourth wash, the slices are then incubated with
secondary antibodies dissolved in 1X PBS with 0.2% TritonX for 1 hour at room temperature with
gentle rocking. Following the secondary incubation, the slices were washed 4 times in an excess
of 1X PBS for 5 minutes with vigorous shaking.
These stained slices are then mounted and dried onto SuperFrost Plus Gold Slides (Ther-
moFisher). The dried slices are then coated with Vibrance anti-fade mounting media (VectaShield,
H1800) and sealed under a .17mm thickness glass cover slip. The mounting media is dried and
hardened overnight at room temperature in the dark. Following the curing of the mounting media,
the edges are sealed with clear nail polish for long term storage either at 4C or room temperature,
per the manufacturer instructions.
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3.2.10 Microscopy Methods
Confocal images presented in this chapter were taken using either the Zeiss LSM710 or the
Zeiss LSM880. All images taken with the LSM710 were taken at a scan area and an airy unit equal
to 1. All images taken on the LSM880 utilized the AiryScan super resolution mode, while the scan
area varied depending on desired field of view and resolution. All images on both Zeiss micro-
scope utilized the 63X oil objective. Additional validation of cell-type localization images were
performed on a Zeiss IM inverted microscope using a 40X water objective or 32X air objective and
a Retiga 2000R CCD camera (Qimaging, USA).
3.2.11 Statistical Analysis Methods
All statistics were performed using R v3.6.3 (CRAN development group, 2019) and all result-
ing figures were generated using the ggplot2 package (Wickham 2016) unless noted. An alpha of
0.05 and a beta of 0.80 were used for the determination if results are statistically significance. The
exact statistical tests will be defined when presenting the results for this chapter. Tukey’s Hon-
est Significant Difference (HSD) is utilized for multiple test corrections when applying post hoc
analysis of significant main effects or interactions in ANOVA-based statistical models.
3.3 Results
3.3.1 Basal Expression Patterns in mPFC
The literature has reported that CNS expression of Ndrg1 is limited to oligodendrocytes (Okuda,
Kokame, and Miyata 2008; Costin, Dever, and Miles 2013). Imunolabeling of the viral injec-
tion site of mice infected with sh-Ndrg1 lentivirus demonstrated that nearly all viral GFP+ cells
co-stained with NeuN, a maker that labels the nuclei most types of neurons (see Figure 3.2).
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Figure 3.2: Microscopy of sh-Ndrg1 infected cells with neuronal marker, NeuN. Imaged at 32X.
Green: GFP+ cells express the tag when infected with lentivirus. Red: Labeling of NeuN+ cells.
White arrows highlight cells that demonstrate strong overlap of NeuN and GFP signal.
Given the significantly increased LORR duration and decreased EtOH consumption observed
following Ndrg1 knockdown, we investigated if neuronal expression of Ndrg1 is possible in the
mPFC of the CNS, a region not previously studied for Ndrg1 expression. We found that NDRG1
did not colocalize with mPFC neurons, but that it did colocalize with both CC1and CNPase (see
Figure 3.3). Thus we conclude that NDRG1 expression in the mPFC is limited to oligodendrocytes.
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Figure 3.3: Cell type expression of NDRG1 in mPFC. A (top row): overlap with neuronal marker,
NeuN. B (middle row): overlap with cytosol marker for oligodendrocytes, CC1. C (bottom row):
over with oligodendrocyte membrane and myelin process marker, CNPase. Note the overlap of
NDRG1 signal with both the oligodendrocyte cell body (see B and C) and within the myelin
process (see C).
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Additionally, we sought to characterize the sub-cellular localization of NDRG1 within the
oligodendrocyte cell type. We found that the Ser330 phospho-form of NDRG1 (Ser330-pNDRG1)
was predominately nuclear with some expression in the cytosol and less in the processes (see
Figure 3.4B). In contrast, the Thr346 phospho-form of NDRG1 (Thr346-pNDRG1) was predomi-
nately expressed in the cytosol and in the myelin processes, with some nuclear expression as well
(see Figure 3.4A). Remarkably, this phosphorylation specific localization pattern is consistent with
that observed in multiple cancer cell lines (Park et al. 2018).
Figure 3.4: Basal sub-cellular localization of phospho-forms of NDRG1within olgiodendrocytes of
mPFC. A: Thr346-pNDRG1 co labeled with CNPase (green) and DAPI (blue). B: Ser330-pNDRg1
co labeled with CNPase (green) and DAPI (blue)
As demonstrated in Figure 3.5, we used the quantification abilities of the ImageJ software
package to compare the mean intensities of pNDRG1 signals for a region of interest (ROI) sur-
rounding 2 cellular compartments. (1) the nucleus: as defined by the outline of the DAPI signal
within the cell (blue). (2) the cyostol: as defined by the outlines of he CNPase signal (green) and
the DAPI signal (blue). Here, we demonstrate a greater mean intensity of Thr346-pNDRG1 signal
in the cytosol relative to the nucleus (see Figure 3.5A). Conversely, we found a greater intensity of
Ser330-pNDRG1 signal in the nucleus relative to the cytosol(see Figure 3.5B).
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Figure 3.5: Comparison of mean intensities of pNDRG1 signal for a region of interest (ROI)
surrounding 2 cellular compartments. (1) the nucleus: as defined by the outline of the DAPI signal
withing the cell (blue). (2) the cyostol: as defined by the outlines of he CNPase signal (green)
and the DAPI signal (blue). Quantification of basal sub-cellular localization of phospho-forms of
NDRG1. (A) Thr346-pNDRG1 (B) Ser330-pNDRG1.
3.3.2 Modulation of Ndrg1 by Acute Ethanol
To begin our ethanol studies, we sought to determine if acute exposures to ethanol would
alter the Ndrg1 transcriptome and/or proteome. First, we utilized qPCR to measure modulation
of Ndrg1 mRNA abundance in the mPFC 4 hours after receiving one of the following doses of
ethanol: 0.0 g/kg (saline control), 0.5 g/kg, 2.0 g/kg, 4.0 g/kg. We normalized the calculated
expression values for all samples in the study relative to a single female control sample, which
allowed us to consider the difference in basal levels of Ndrg1 expression between male and female
mice in the analysis. The 2-way ANOVA analysis revealed significant main effects of (1) ethanol
dose (P = 5.7E-6) and (2) sex (P = 1.52E-14) and their interaction (P = 0.0013) on the detected
levels of Ndrg1 expression (see Figure 3.6). A post hoc Tukey HSD analysis of all sex and ethanol
dose comparisons was performed to correct the p-values of all comparisons. Post hoc testing
revealed a significant induction of Ndrg1 expression in female mice at the highest dose (4.0 g/kg)
relative to the saline control group (P < 0.0001), as shown in Figure 3.6A. Conversely, the male
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Figure 3.6: qPCR analysis of Ndrg1 transcript expression 4 hours after one of the following acute
ethanol exposures: 0.0 g/kg (saline control), 0.5 g/kg, 2.0 g/kg, 4.0 g/kg. (A) dose response for
female mice. (B) dose response for male mice.
mice (Figure 3.6B) did not display any alterations in Ndrg1 expression following acute ethanol (P
> 0.89 for all ethanol dose comparisons). Additionally, no difference was detected between basal
levels (0.0g/kg) of Ndrg1 in female and mice in the saline control groups (P = 0.465). Likewise, no
differences were detected between the group of saline control female mice and any of the 3 ethanol
dosed groups of male mice ( P > 0.19 for all comparisons).
After considering the transcript response to acute ethanol, we utilized Western blotting to mea-
sure changes in two different phospho-forms of NDRG 30 minutes following one of the following
doses of ethanol: 0.0 g/kg (saline), 0.5 g/kg, 2.0 g/kg, 4.0 g/kg. In the following acute ethanol
Western blotting analyses, we utilized a 2-way ANOVA design that considered the main effects
and interactions of ethanol dose and sex. For demonstration of concept of our Western blotting
quantification setup, we briefly show the imaged membrane Thr346-pNDRG1 staining for male
mice following chronic ethanol drinking (see Figure 3.7). In particular, we note variation of the
quantification protein signal, Thr346-pNDRG1 (see Figure 3.7A) across the samples. However,
we see no variation of normalization control gene, GAPDH (see Figure 3.7B), indicating that our
Western blotting quantification system is valid for our experimental design.
41
Figure 3.7: Example of Western blot imaging and quantification for Thr346-pNDRG1 in chronic
drinking male mice. (A) shows the signal of the 800CW secondary antibody for Thr346-pNDRG1
(in green). The intensity quantification of the Thr346-pNDRG1 displays variation of signal be-
tween samples (right of A). (B) shows the signal 680LT secondary antibody for the normalization
control, GAPDH (in red). Note the constant, non-varying signal of GAPDH across the samples
(right), indicating that GAPDH is an appropriate normalization gene for these Western blotting
studies.
As expected, we found no significant main effects of ethanol dose (PEtOHdose = 0.198) or sex
(PSex = 0.846) and no significant interactions of between the main effects (PEtOHdose:Sex = 0.970)
for the total NDRG1 signal following acute ethanol (see Figure 3.8C). Here, the total NDRG1
signal is first normalized using the GAPH signal as a loading/normalization control. The signals
for each ethanol treated samples is then normalized by dividing by the average NDRG1 signal of
the saline control group in both sexes. This last step results in the control group having a normal-
ized expression of 1.0 for each sex (see Figure 3.8C). Next, we analyzed the two phospho-forms
of pNDRG1 by normalizing the phospho-signal to the normalized total NDRG1 signal for each
sample. Finally, the signals for each ethanol treated sample is then normalized by dividing by the
average pNDRG1 signal of the saline control group in both sexes to normalize the control groups
to an average of 1.0 for each sex (Figure 3.8A,B).
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Figure 3.8: Modulation of phospho and total NDRG1 following acute ethanol dose re-
sponse. Graphical representation of 2-way ANOVA investigating effects of ethanol dose and
sex. (A) Ser330-pNDRG1 results: significant main effect of sex (### < 0.05) detected. (B)
Thr346-pNDRG1 results: significant main effect of ethanol dose (*** < 0.05) detected. (C) Total
NDRG1 results: no significant effects or interactions detected
Following these normalization steps, we found a main effect of sex (PSex = 0.046) was observed
for the Ser330 phospho-form of NDRG1, but there was no main effect of ethanol dose (PEtOHdose
= 0.653) or any significant interactions (PEtOHdose:Sex = 0.423) the between the main effects (see
Figure 3.8A) . Conversely, the signal Thr346 phospho-form of NDRG1 demonstrated a main effect
of ethanol dose (PEtOHdose = 0.027), but was unaffected by either the main effect of sex (PSex =
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0.105) or an interaction (PEtOHdose:Sex = 0.6302) between the main effects (see Figure 3.8). There-
fore, we collapsed the sexes to increase our statistical power and reduce the dimensions to a 1-way
ANOVA that only considers the effect of the ethanol treatment dose (see Figure 3.9). Post-hoc
testing of the effect of ethanol treatment dose on Thr346-pNDRG1 expression was conducted in
a pairwise fashion. Following multiple test corrections with Tukey’s HSD, it was determined that
there was a significant down regulation (Pad justed = 0.017) of the Thr346 phospho-form of NDRG1
at the highest dose (4.0 g/kg) relative to the control saline animals (see Figure 3.9).
Figure 3.9: Levels of Thr346-pNDRG expression in mPFC are altered by acute ethanol exposure.
Sexes are collapsed in this analysis, based on the results of the 2-way ANOVA. Post hoc analysis
with Tukey’s HSD revealed that a significant decrease in Thr346-pNDRG1 was detected in the 4.0
g/kg ethanol dose group relative to the saline treated control group (Pad justed = 0.017).
Additionally, rather than simply asking if levels of phospho-NDRG1 are altered following
acute ethanol, we utilized IHC methods to determine if sub-cellular distribution of phospho-NDRG1
forms is altered by acute ethanol. We delivered a dose of 2.0 g/kg and the mice were transcar-
dially perfused 30 minutes following the ethanol injection. The dose of 2.0 g/kg was chosen as
a more accurate representation of human levels of intoxication and the time point was set to be
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the same as previously used in the acute ethanol dose response experiment. Both phospho-forms
were investigated using the super resolution AiryScan functionality of the Zeiss LSM880. The
phospho-NDRG1 forms are co stained with CNPase, as a marker of oligodendrocyte cell mem-
branes and the myelin processes, and DAPI, as a marker of nuclear compartment. As described
above and demonstrated in Figure 3.5, we used FiJi to quantify signal intensity of the phospho-NDRG1
in the cytosol and the nucleus by drawing ROIs based on the compartments that are defined
using the CNPase and DAPI costains. We imaged a total of 90 cells per treatment group by
3 coronal slice are used per animal, where 5 well shaped oligodendrocytes are imaged in the
mPFC region per hemisphere. We found that 2.0 g/kg of acute ethanol significantly alters the
ratio of nuclear/cytosol mean intensities signals for Ser330-pNDRG1 (P < 0.01), but not for
Thr346-pNDRG1 (see Figure 3.10). In specific, we determined that acute ethanol results in higher
levels of nuclear Ser330-pNDRG1 signal relative to cytoplasmic signal (see Figure 3.10A).
Figure 3.10: Comparison of nuclear to cytosol ratio of phospho-NDRG1 signal following acute
ethanol exposure (30 minutes after 2 g/kg, ip). (A) Ser330-pNDRG1. (B) Thr346-pNDRG1. N
= 3 per treatment (ratio values for each N is derived from an average of 30 imaged cells over 3
coronal slices). Student’s t-test (* P < 0.05)
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3.3.3 Modulation of Ndrg1 by Chronic Consumption of Ethanol
Recent studies from the Miles laboratory have shown marked increase in Ndrg1 correlation
with myelin gene expression in mPFC following one year of chronic ethanol consumption in rhesus
macaques (Bogenpohl et al. 2019). To complement our data on acute ethanol exposure, we set out
to determine if Ndrg1 was altered at the transcript or protein level following 5 weeks of chronic
intermittent consumption of ethanol in a mouse model. We also determined expression profiles of
myelin genes at both the transcript and the protein level. As documented in the dissertation by Van
der Vaart 2018, the IEA protocol produced a number of ethanol drinking phenotypes. While there
is no change in total daily ethanol consumption or preference over the course of the study, the binge
readings measured an increased preference for ethanol (see Figure 3.11B) and ethanol consumed
(see Figure 3.11A) in the first 2 hours over the course of the 5-week study. As expected, the female
mice consumed higher amounts of ethanol than males over a 24-hour period (see Figure 3.11E).
Additionally, BEC measurements of the 12 selected mice at the 2 hour time mark showed that
both males and female had significantly elevated BEC levels (180 mg/dL), indicating the mice
were indeed consuming intoxicating levels of ethanol soon after the drinking bottle was provided
(see Figure 3.12A). Both the male and the female mice had and average BEC of approximately
100mg/dL after 2 hours of access to the ethanol (see Figure 3.12B). Consistent with this finding,
we report that both male and female mice escalated their ethanol consumption (Figure 3.11C) and
preference (Figure 3.11D) to very similar levels by the 15th access day in the study.
After validating the effectiveness of our IEA drinking paradigm, we investigated Ndrg1 at
transcript level expression using qPCR following the 5 weeks of chronic ethanol exposure. Here,
we found a borderline significant main effect of treatment (P = 0.051) on expression levels of Ndrg1
when utilizing a 2-way ANOVA model that considered both treatment and sex (see Figure 3.13A).
We did not observe any effects of sex, so data was collapsed across sexes and analyzed by simple
t-test based statistics. Once collapsed, we observed a statistically significant induction of Ndrg1
mRNA in the mPFC (P = 0.041) following 5 weeks of chronic ethanol drinking (see Figure 3.13B).
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Figure 3.11: Drinking patterns over time in 5 week 2-bottle choice IEA study. Displays both the
ethanol consumption (A, C, D) and preference (B, D, F). 24 hour measurements are compared with
2 hour binge measurements in A, B. Male and female measurements at the 2 hour binge measure-
ment are compared in C, D. Male and female measurements at the 24 total daily measurement are
compared in E, F.
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Figure 3.12: BEC measurements of select mice at the 2 hour binge reading point after 5 weeks
of 2-bottle choice IEA drinking. Blood draws occurred during the second to last drinking session.
(A) Individual BEC measurements for all selected mice. (B) Average BEC values per sex.
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Figure 3.13: qPCR analysis of Ndrg1 transcript levels following 5 weeks of chronic ethanol ex-
posure. (A) Graphical representation of 2-way ANOVA model investigating the effects of ethanol
drinking and sex. A borderline main effect of main effect of ethanol drinking was detected (#, P =
0.051), while no effects of sex were detected. (B) Sexes are collapsed to increase statistical power.
Results in a significant induction of Ndrg1 transcript following chronic ethanol drinking
We next determined if myelin-related transcripts were altered by the chronic ethanol exposure,
since dysregulation of myelin genes are thought to contribute in part to the pathology of alcohol
abuse. We measured the expression of a panel of myelin genes which have been shown to be
altered in brain tissue from human alcoholics (Mayfield et al. 2002; Liu et al. 2006) or animal
models (Kerns et al. 2005; Wolstenholme et al. 2017): Mag, Mbp, Plp1 and Mobp. Sexes were
collapsed to increase power since there was no main effect or interaction with the treatment group
for any gene. In short, we observed no changes in our panel of 4 myelin genes between the ethanol
drinkers and the water controls when the treatment groups are compared by simple Students t-tests.
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Figure 3.14: qPCR analysis of a panel of 4 myelin genes following 5 weeks of chronic consumption
of ethanol. No effects or interactions of sex or ethanol treatment were detected with a 1-way
ANOVA analysis after collapsing both sexes. (A) Mag (B) Mbp (C) Plp1 (D) Mobp
After documenting the modest induction of Ndrg1 transcripts, we investigated the effects of
chronic alcohol consumption on NDRG1 protein levels in the mPFC using Western blotting. At
the same time, we also quantified the predominant and main protein in CNS myelin, MBP, to get
a snapshot of general levels of myelin expression in the mPFC. In brief, we found no significant
changes in any phospho or total form of NDRG1 or MBP, in males or females, following 5 weeks
of chronic ethanol drinking (see Figure 3.15 and Figure 3.16).
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Figure 3.15: Western blots for NDRG1 and MBP following chronic ethanol exposure in female
and male mice. Top panel: female results. Bottom panel: male results. No effects or interac-
tions of sex or ethanol treatment were detected with a 2-way analysis. (A) Ser330-pNDRG1 (B)
Thr346-pNDRG1 (C) total NDRG1 (D) total MBP
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Figure 3.16: Scans of membranes stained for NDRG1 and MBP following chronic ethanol expo-
sure in female and male mice. Top panel: female results. Bottom panel: male results. Stains
and imaging of membranes are performed in the following order: (1) Thr346-pNDRG1, (2)
Ser330-pNDRG1, (3) total NDRG1 (4) total MBP
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3.4 Discussion and Conclusions
The prior literature and the findings presented here provide strong evidence that Ndrg1 is only
expressed in oligodendrocytes in the mPFC region of the cortex. We also found for the first time
in brain tissue that the sub-cellular localization of Ser330-pNDRG1 and Thr346-pNDRG1 in CNS
oligodendrocytes are consistent with that observed in many studied cancer cell lines (Park et al.
2018). This suggests that the mechanisms behind the phospho-protein distributions are conserved
in many cell types that express Ndrg1. Our studies on ethanol regulation of Ndrg1 showed that
acute ethanol altered both the mRNA transcript abundance and the sub-cellular distribution of
Ndrg1, while chronic ethanol consumption also altered Ndrg1 transcript abundance.
Since we determined original lentiviral knockdown of Ndrg1 that altered ethanol related phe-
notypes (see Figure 2.6) mainly appeared to infect NeuN expressing neurons (see Figure 3.2),
it suggests one of the those possibilities: enough oligodendrocytes are in fact being infected by
the lentiviral vector to drive the phenotype, Ndrg1 expression in neurons was below the sensitiv-
ity of our IHC studies, or that the shRNA for Ndrg1 has unexpected off-target effects in mPFC
neruons. Some of our reported findings displayed sex specific effects, such as where the induction
of Ndrg1 after acute ethanol only occurred in the female mice (see Figure 3.6A). In many cases the
reported phenotypes were observed in both sexes, such as the induction of Ndrg1 transcript fol-
lowing 5 weeks of ethanol consumption (see Figure 3.13) or the decrease in total mPFC levels of
Thr346-pNDRG1 that occurred following acute ethanol (see Figure 3.9). These results highlight
the fundamental importance of utilizing both female and female mice to more fully understand
the intricate dynamics of Ndrg1 regulation in the context of ethanol exposure in the mPFC. While
our acute ethanol immunofluorescence study only used male mice, a noted increase in the ratio of
nuclear-to-cyostol signal of Ser330-pNDRG1 in mPFC oligodendrocytes was observed (see Fig-
ure 3.10). It would be very interesting to expand this particular study with both male and female
mice.
While the induction of Ndrg1 transcript did occur after 5 weeks of ethanol access, we did not
see alterations myelin transcripts (see Figure 3.14). Furthermore, we did not detect any differences
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total NDRG1, phospho-NDRG1, or MBP protein abundances (see Figure 3.15). Given that the
Rhesus macaques were given 1 year of access to ethanol in the study before Ndrg1 was strongly
correlated with myelin gene expression (Bogenpohl et al. 2019), it is likely that any altered Ndrg1
expression would become more correlated to myelin gene expression if the IEA study continued
for 3-6 months rather than just 5 weeks. The lack of additional literature regarding Ndrg1 and
ethanol drinking in mouse models leaves us to speculate that additional time in our IEA protocol
would induce further alteration of Ndrg1 expression, leading to alterations in the expression of the
myelin genes tested in this chapter.
On the whole, the results do demonstrate that Ndrg1 is modulated by both acute and chronic
ethanol exposures. We observed inductions of Ndrg1 at the mRNA in in the acutely and chroni-
cally. We noted decreases in Thr346-pNDRG1 levels after acute ethanol, and we have evidence
that a translocation of Ser330-pNDRG1 into the nucleus occurs following moderate doses of acute
ethanol. It is also interesting that there is a decrease in the abundance of Thr346-pNDRG1 at the
western blot level following the highest doses of ethanol, yet the Ser330-pNDRG1 form showed
the alterations in cellular distribution following a moderate dose of ethanol. To followup, it would
be interesting to perform acute ethanol IHC at higher doses of ethanol. Perhaps Thr346-pNDRG1
does not show translocation effects until the very high doses where total Thr346-pNDRG1 abun-
dance is significantly decreased (Figure 3.9).
While the male mice in the acute dose response experiment did not display increased amounts
of Ser330-pNDRG1 at any dose(see Figure 3.8A), there were significant alterations in the sub-cellular
localization of Ser330-pNDRG1 in male mice following 2 g/kg of acute ethanol. These data
combine to suggest that there is a translocation of Ser330-pNDRG1 to the nucleus from the cy-
tosol rather than new phosphorylation of NDRG1 that resides in the nucleus. Conversely, the
Thr346-pNDRG1 results suggest that the decreases in mPFC levels of Thr346-pNDRG1 following
acute ethanol result in equal levels of dephosphorylation in both the nucleus and the cytosol.
It is curious that we saw a modest induction of Ndrg1 mRNA transcript following chronic
ethanol exposure, but there was no change in the amount of NDRG1 at the protein level. There
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was also no change in relative amounts of either of the two phospho-NDRG1 forms. It could
be possible that a compensatory mechanism prevents additional mRNA from being translated as
repeated consumption of ethanol. Since we sacrificed the mice 24 hours after their final drinking
session, it could also be that the phospho-NDRG1 staining patterns seen acutely are still occurring
each day, but that the effect is completely washed out 24 hours later.
The data thus far suggests the myelin genes in the mPFC are not influenced by acute or chronic
exposure to ethanol. But, it is not surprising that we found no changes in myelin gene expression
following just 5 weeks of ethanol consumption. It would probably take a significantly longer
drinking study that spanned months to detect perturbations in mPFC myelin gene expression from
voluntary ethanol consumption.
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Chapter 4
Genetic Effects of Ndrg1 knockout in myelinating
cells
4.1 Introduction
In Chapter 3, we confirmed that Ndrg1 expression is limited to oligodendrocytes in the mPFC
and likely the whole of the CNS. In multiple different models of ethanol exposure, we observed
regulation of Ndrg1 at the from the transcript levels down to the phosphorylation localization of the
protein. In particular, the recently performed network analysis has identified Ndrg1as a hub gene
in the low drinking line (Colville et al. 2017). However, the authors suggested that none of the
hub genes, including Ndrg1, were directly linked to ethanol preference. As discussed in Chapter 2,
additional unpublished data in our lab has determined that lentiviral mediated knockdown of Ndrg1
expression in the mPFC of mice altered sensitivity-related phenotypes and reduced preference
for higher concentrations of ethanol in a 3-bottle drinking paradigm (Wohlstenholme/Farris, in
preparation). There is substantial data suggesting Ndrg1 is both regulated by ethanol, and may
modulate ethanol behaviors. We therefore wanted to devise a mouse model to better test how
Ndrg1 levels modulate ethanol behaviors by deleting the gene specifically in myelin producing
cells, which we hypothesize are solely responsible for effects of Ndrg1 deletion or mutation on
ethanol behaviors.
The interactions between central nervous system Ndrg1 and myelination are largely unan-
swered questions. In contrast, Ndrg1’s importance in peripheral myelination and nerve function
is much more well understood and studied. As previously discussed, multiple studies show that
mutant forms of Ndrg1 result in CMT4D-like neuropathy in humans, dogs, and mice. As described
in Chapter 2, linkage disequilibrium studies with human breast cancer patients that found SNPs in
regulatory elements of Ndrg1 correlated with severity of Paclitaxel-induced peripheral neuropathy
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(PIPN) (Sundar et al. 2014). Follow-up work found that nerve levels of Ndrg1 in excised breast
tissue inversely correctly with the severity of PIPN that is experienced (Sundar et al. 2016). Periph-
eral neuropathy is one of the most common end-organ toxicities of chronic ethanol consumption
(Chopra and Tiwari 2012). While there currently is no known link between Ndrg1 expression lev-
els and ethanol-induced neuropathy, our findings on ethanol regulation of Ndrg1 and prior reports
linking the gene to genetic or Paclitaxel-induced peripheral neuropathies, certainly support such a
hypothesis. Thus, Ndrg1 levels in the peripheral nerve could alter the likelihood for development
of ethanol induced neuropathy symptoms.
A typical downside to constitutive deletion models is the potential for compensatory mecha-
nisms that can form when a gene is deleted in all cells from the start of conception. These compen-
satory mechanisms can easily confound the results of such studies, making it unclear whether any
observed biological alterations are driven by the lack of gene function or as a result of compen-
satory changes in the transcriptome from the gene knockout. To circumvent these shortcomings,
we designed and bred a mouse line that allowed us to conditionally knockout Ndrg1 in all myeli-
nating cells. We utilized this mouse line to have fine control of the exact time point when Ndrg1 is
knocked out. Because the knockout is in all myelinating cells, we were able to devise experiments
to investigate the effects of conditional deletion in the context of the CNS and the PNS.
First, we sought establish a more clear link between the effects of Ndrg1 deletion on frontal
cortex myelin, and ethanol related behaviors. We hypothesized that conditional knockout of Ndrg1
in early adulthood would increase acute ethanol sensitivity, which would result in decreased con-
sumption and preference, particularly for higher concentrations of ethanol. Second, we hypothe-
sized that Ndrg1 deletion would have deleterious peripheral effects that would worsen with time
that it would increase sensitivity to toxic insults, such as Paclitaxel administration. In the end,
we will conclude with an experiment that attempts to begin the investigation for the cross-play
that occurs between these central and peripheral actions of Ndrg1 deletion. In this final experi-
ment, we hypothesized that repeated high doses of ethanol would induce signs of peripheral nerve
dysfunction in a much shorter time scale than would be expected.
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4.2 Materials and Methods
4.2.1 Drugs Used in Chapter
Tamoxifen (Sigma Aldrich, #T5648) was dissolved in Sunflower oil to a concentration of
20mg/mL using 30 minutes of sonication in a Branson ultrasonic cleaner at 37C. The tamoxifen
solution was sterile filtered and stored at 4C in the dark for the duration of the study.
Ethanol solutions in the chapter dissolved 100% pharmacological grade ethanol into either tap
water or normal saline (0.9%) to the indicated concentration.
Paclitaxel (Torcis, Bristol, United Kingdom) was dissolved in a 1:1:18 mixture of ethanol :
Emulphor-620 (Rhone- Poulenc, Inc., Princeton, NJ) : distilled water.
4.2.2 Tamoxifen Treatment
Each mouse was injected with the prepared tamoxifen solution for a per weight dose of approx-
imately 75 mg/kg, every 48 hours over a 5 day period (3 total injections). Validation of deletion was
performed via immunohistochemistry and Western blotting. Utilizing the described mouse lines,
myelinating cell specific deletion of Ndrg1 was induced by delivering tamoxifen (Signa-Aldritch,
T5648) dissolved in sunflower oil (Signa-Aldritch, S5007) by i.p injection. The injection volume
of 100uL was used and all experimental mice began the tamoxifen regiment between 8 weeks and
16 weeks of age.
4.2.3 Tamoxifen Inducible Cre Recombinase Mouse Line
In order to drive Cre expression only in myelinating cells, we utilized a Tamoxifen inducible
mouse line where Cre expression is driven by the promoter of the most abundant major myelin pro-
tein in the CNS, myelin proteolipid protein protein (PLP). This Plp-promoter tamoxifen inducible
Cre mouse line (Plp-Cre-ERT, Jackson Laboratory #005975) based on a pure B6J-background.
Expression of promoter driven Cre line as Proteolipid protein (PLP) is exclusive to myelinating
cells.
Our floxed-Ndrg1 mouse line was derived from ES cells of a B6N background that were ac-
quired from the UC Davis Knockout Mouse Project KOMP Repository (https://www.komp.org,
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#38738). These “knockout first” mice, as shown in Figure 4.1, were first bred to a Flipase-producing
line to delete the entire region between the two FRT sites – leaving a modified gene with just two
loxP sites that flank exons 6 and 7 (see Figure 4.1). The resulting mice were then crossed with a
Plp-promoter tamoxifen inducible Cre mouse line (Plp-Cre-ERT, Jackson Laboratory #005975)
based on a B6J-background. Following this cross, the resulting mouse line then backcrossed
against the B6J reference for multiple generations for colony generation. Using this method, 3
PCNdrg1mouse lines were established after the 3rd, 4th, and 7th generation of backcrossing. The
lines created from the 3rd the 7th generations was homozygous for the floxed-Ndrg1 allele, gener-
ating a full knockdown of Ndrg1 in Plp expressing cells. while the 4th generation was heterozy-
gous for the floxed-Ndrg1 allele. All mice were either heterozygous for the Cre expressing allele
or null/null. The Cre-null/null are used as the experimental control since these mice is unable to
produce the Cre gene product needed to delete the floxed-Ndrg1 alleles.
For all experiments conducted in this chapter, mice of both genders were bred in the VCU
Transgenic Core and delivered to our vivarium at 8 weeks of age. All mice brought into the
vivarium remained group housed (N=3 or 5 per cage) on corn cob-based bedding in ventilated
rack-mounted cages. The vivarium room was temperate controlled and maintained a 12 hour on-off
light cycle. To begin every experiment in this chapter, all mice receive 1 week of tamoxifen
injections in their original group housing, as described above. All ethanol drinking studies were
performed in the OOV, while the control drinking studies were performed in free standing cages
with Sani-Chip bedding. For all other behavioral studies, mice remained group housed (N=3 or 4
per cage) on corn cob-based bedding the vivarium for the duration of the studies. Habituation to
acute intraperitoneal injections began at 10 weeks of age. The group housed mice were maintained
in static rack-mounted cages with active air circulation. All cages were changed once a week
for the duration of the studies. All mice had ab libitum access to standard chow (Teklad food
pellets, #7912) and tap water. All procedures performed on the animals within our laboratory
protocol, which was approved by the VCU Institutional Animal Care and Use Committee and
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were compliant with the NIH Guide for the Care and Use of Laboratory Animals. Unless noted
otherwise, all experiments within this chapter contained equal numbers off male and female mice.
Figure 4.1: Schematic of NDRG1 KO line genetic manipulations. Grey boxes indicate the location
of the numbered exons. Figure adapted from KOMP website. During the first breeding step to
Flipase expressing mice removes the lacZ expression reporter and the NEO cassette, along with
the loxP site contained between the FRT sites. This generates a line of a line of floxed-Ndrg1 with
2 loxP sites that flank exons 6 and 7 of Ndrg1 (see red box on diagram)
4.2.4 Prepared Solutions
The injection solution for the IHC studies was either 0.9% normal saline or ethanol diluted
to 20% (v/v) in normal saline. The drinking solutions provided for the IEA study were either tap
water or ethanol diluted to 20% (v/v) in tap water. For the acute dose-response study, all ethanol
solutions were diluted to 18% (v/v) in normal saline. The formaldehyde solution (4% w/v) was
created by dissolving powdered para-formaldehyde into 0.9% saline using heat (65◦C) and by
adding 1N NaOH to bring the solution pH to 10. Once the para-formaldehyde powder was fully
dissolved under the described conditions, the solution was cooled and 1N HCL acid was added
drop wise to bring the formaldehyde solution to physiologic conditions (pH = 7.4).
4.2.5 Ethanol Exposure Models
The drinking data presented in this chapter was generated using a modified 3-bottle version
of the Intermittent Ethanol Access (3B-IEA) that was described in Chapter 3 (see Figure 3.1). In
brief, the main modifications to the protocol were the switch to 3-bottle choice and removal of the
2 hour binge drinking measurements. As described previously, he mice were given access to 3
bottles (water, 15%,30% (v/v) EtOH) for 24 hours every other day for 5 weeks of drinking. The
drinking bottles were provided with access to the drinking bottles are provided within 30 minutes
of the beginning of the 12 hour dark cycle.
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4.2.6 Loss of Righting Reflex (LORR
Mice were given a high dose ethanol (3.8 g/kg, i.p.) injection of 20% ethanol v/v in normal
saline. The mice were then rotated in a clear plastic tube every 5 seconds until they are unable
to right themselves. At this point, time for LORR onset was recorded. Animals were then placed
supine in wedge-shaped troughs and monitored until they are unable to right themselves within
30 seconds being rotated back onto their back. Once the mouse meets this criteria, duration for
return of righting reflex was recorded. Animals with onset times greater than 4 minutes were
considered LORR failures and removed the study. Statistical analysis was performed within-sex
using unpaired Student’s t-tests to compare Cre+ and Cre- animals. Sample sizes for the PCNdrg1
mice included 10 per group.
4.2.7 Western Blotting
For all western blot studies in this chapter, tissue homogenization was performed using 1X
RIPA lysis buffer (50 mM Tris, 150 nM NaCl, 1% NP40, 5 mM EDTA, and 0.5% SDS). Microdis-
sected tissue was homogenized using 2 to 4 short pulses with an ultrasonic sonicator over ice.
To prevent protease and phospatase activity in the homogenized samples, 100X HALT Protease
and Phosphatase Inhibitor Cocktail (ThermoFisher, #78440) was diluted to 1X in all RIPA buffers
prior to homogenization. The homogenized solutions were partitioned into aliquots and imme-
diately frozen at −80◦C. Total protein concentration was determined by utilizing a Pierce BCA
Protein Assay Kit (ThermoFisher, #23225), to allow for equal protein loading. Before performing
an immunoblot, the proteins in the homogenized samples were denatured by heating the sample
dissolved in NuPage Reducing Agent (ThermoFisher, NP0004) and 4X Protein Sample Load-
ing Buffer (LiCor, #928-40004) in a heat block for 10 minutes at 70◦C. Both the electrophoresis
and the transfer steps were performed using the Xcell Surelock Mini Cell System (ThermoFisher,
EI0001). The denatured protein samples were loaded into NuPage 4-12% Bis-Tris 17-well gels
(ThermoFisher, NP0329BOX). Once equal amounts of total protein are loaded onto the gel, the
proteins are first separated by size using electrophoresis at 100V. The size separated gels were then
transferred onto Immobilon-FL PVDF Membrane (Millipore, IPFL00005) by applying 12V at 4C
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for 16 hours using NuPage Transfer Buffer (ThermoFisher, NP0006). Following transfer, the mem-
branes were briefly rinsed in milliQ water and were air dried for at least 1 hour to promote perma-
nent binding of transferred proteins. The membranes were then re-hydrated using 100% methanol
and rinsed with milliQ water. The membranes were then blocked in Licor Intercept Blocking
Buffer (Licor, #927-60001) for 1 hour before the immediate application of primary antibodies,
diluted in 1X blocking buffer containing .2% Tween-20. The primary antibodies were incubated
overnight at 4C before the solution is washed 4 times with 1X TBS with 0.1% Tween-20. The
membranes were then incubated with secondary antibodies were diluted into 1X blocking buffer
with 0.2% Tween-20, and then applied for 1 hour at room temperature. The membranes were then
washed 4 times with 1X TBS with 0.1% Tween-20, followed by rinses in 1X TBS to remove the
residual tween-20 from the washes. The membranes were stored submerged in 1X TBS in the dark
at 4C until ready to image. Imaging was performed using the Odyssey Infrared Imaging System
(Licor, #9120). The experimental proteins were stained using the species-specific 800CW sec-
ondary at 1:30,000 dilution. The loading control and normalization protein, GAPDH, was stained
using the 680LT anti-mouse antibody specific to mouse IgG1 at a concentration of 1:50,000. All
scans were analyzed and quantified using the FiJi image analysis software package (ImageJ, NIH).
Because the membrane was thoroughly dried following transfer, the membranes can be safely
stripped of the primary/secondary antibodies multiple times without noticeable protein loss. The
stripping of the membranes was performed using 1X NewBlot IR Stripping Buffer (Licor, #928-40028)
for 20 minutes with vigorous shaking, followed by multiple wash steps. A new aliquot of the sec-
ondary antibody staining solution is then incubated on the stripped membrane and re-imaged to
determine efficacy of the stripping of the signal. Using this methodology, we were able to im-
age multiple targets on a single membrane, including: anti-NDRG1, anti-MBP, and finally with
anti-PLP.
For all protein studies presented in this chapter, tissue homogenization was performed in 1X
RIPA lysis buffer. To prevent protease and phospatase activity in the homogenized samples, 100X
HALT inhibitor (Thermo Fisher) was diluted to 1X in all RIPA buffers prior to homogenization.
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For the frontal cortex studies, the frontal lobe dissection tissue was first homogenized with a Poly-
tron blade-type homogenizer (Brinkmann, PT2000) homogenizer, and then followed by 2-3 short
bursts with the sonication probe. For the sciatic nerve studies, 2 pooled sections of sciatic nerve
from the left and the right hind leg are homogenized in a Beadbug6 homogenizer using 1.5mm
stainless steel beads. In both cases, the remaining tissue debris is spun down at 10,000g for 10min-
utes and the resulting supernatant is extracted.
In all cases, the homogenized solutions were aliquoted and immediately frozen at -80C. Before
performing an immunoblot, the proteins in the homogenized samples were denatured by heating
the sample dissolved in NuPage Reducing Agent (Thermo Fisher) and 4X Protein Sample Load-
ing Buffer (LiCor, Lincolin, NE) in a heat block for 10 minutes at 70C. Both the electrophoresis
and the transfer steps were performed using the Xcell Surelock Mini Cell kit (Thermo Fisher).
The denatured protein samples were loaded into NuPage 4-12% Bis-Tris 17-well gels (Thermo
Fishger). Once loaded, the proteins are first separated by size using electrophoresis at 100V while
submersed in 1X LiCor MES Running Buffer (LiCor). The separated gels were then transferred
onto Immbolin FL PVDF membrane using 12V at 4C for 16 hours using NuPage Transfer Buffer
(Thermo FIsher). Following transfer, the membranes were briefly rinsed in milliQ water and were
air dried for at least 1 hour to promote permanent binding of transferred proteins. The membranes
are then rehydrated using 100% methanol and rinsed with milliQ water. The membranes were then
blocked in Licor Intercept Blocking Buffer (Licor) for 1 hour before the immediate application
of primary antibodies, diluted in 1X blocking buffer containing .2% Tween-20. The primary an-
tibodies were incubated overnight at 4C before the solution is washed 4 times with 1X TBS with
0.1% Tween-20. The membranes were then incubated with secondary antibodies were diluted into
1X blocking buffer with 0.2% Tween-20, and then applied for 1 hour at room temperature. The
membranes were then washed 4 times with 1X TBS with 0.1% Tween-20, followed by rinses in 1X
TBS to remove the residual tween-20 from the washes. The membranes were stored submerged in
1X TBS in the dark at 4C until ready to image. Imaging was performed using the Licor Odessy
classic scanner (Licor). The experimental proteins were stained using the species-specific 800CW
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secondary at 1:30,000 dilution. The loading control / normalization protein was stained using the
680LT anti-mouse antibody specific to mouse IgG1 at a concentration of 1:50,000. All membranes
were probed with 3 different antibodies in the following order: anti-NDRG1, anti-MBP, and finally
with anti-PLP. Between each probing, the membranes were stripped of primary and secondary an-
tibodies using LiCor NewBlot IR Stripping Buffer (#92840028)) All scans were analyzed and
quantified using the FiJi image analysis software package(ImageJ, NIH).
4.2.8 Immunohistochemistry
All mice were perfused with transcardial administration of a 4% formaldehyde solution (in
1X PBS)while anesthetized with high doses of isoflurane. The mice were first flushed with pure
1X PBS to remove the remaining blood before the 4% formaldehyde was injected. The perfused
brains were then removed from the skull and transferred to a vial of fresh 4% formaldehyde for an
overnight post-fixation step. The brains are then placed into a 30% sucrose solution dissolved in
1X PBS for dehydration of the remaining water. Once the brains were fully dehydrated and sunk
to the bottom of the sugar solution, they were snap frozen in a vial of isopentane that was cooled
to -80C using dry ice and then stored at -80C until they are ready to proceed. The frozen brains
are then cut into 20um thick coronal sections using a Leica CM3050 cryostat (Leica Biosystmes,
Wetzlar, Germany). The sliced sections stored as free-floating sections that were submerged in a
1X PBS solution containing 0.02% sodium azide to preserve and prevent bacterial growth. The
slices were stored in order along the wells of a 24-well plate.
Prior to staining of the coronal slices, the antigens that are masked by protein crosslinking are
recovered by placing the slices in Citrate Acid Buffer (pH = 6.0) and heating at 80C for 20 minutes
with shaking, followed by a 30 minute cool-down step at room temperature with vigorous shaking.
Following this antigen retrieval process, the sections are then permeabilized and blocked in 10%
goat serum with 0.2% Triton X100 for 30 minutes are room temperature. The sections were then
incubated overnight at 4C with primary antibodies that are dissolved in 1XPBS with 0.2% Triton-X
with gentle rocking. The slices are then washed 4 times in an abundance of 1X PBS for 5 minutes
with vigorous shaking. Following the fourth wash, the slices are then incubated with secondary
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antibodies dissolved in 1X PBS with 0.2% TritonX for 1 hour at room temperature with gentle
rocking. Following the secondary incubation, the slices were washed 4 times in an excess of 1X
PBS for 5 minutes with vigorous shaking.
These stained slices are then mounted and dried onto SuperFrost Plus Gold Slides (Ther-
moFisher). The dried slices are then coated with Vibrance anti-fade mounting media (VectaShield,
H1800) and sealed under a .17mm thickness glass cover slip. The mounting media is dried and
hardened overnight at room temperature in the dark. Following the curing of the mounting media,
the edges are sealed with clear nail polish for long term storage either at 4C or room temperature,
per the manufacturer instructions.
4.2.9 Tastant Alteration Studies
A single cohort of ethanol-naive PCNdrg1 mice was utilized for both tastant studies. The
mice were first given access to continuous free access to two bottles: one containing tap water
and the other containing water with quinine (0.05 mM concentration) for 4 days. After the 4th
day, the mice were then giving access to another two bottles: one containing tap water and the
other containing saccharin (2 mM, 0.037% w/v). Volume consumed readings were taken every 24
hours. When the bottles are measured and refilled, the placement of the bottles on the cage top is
alternated to prevent the development of cage side preference.
4.2.10 Ethanol Pharmacokinetics
Alterations in ethanol metabolism were tested using a large dose bolus of acute ethanol. The
mice were dosed with 4 g/kg of 20% (v/v) ethanol in 0.9% normal saline. Following the injections,
retro-orbital bleeds were collected in lavender topped EDTA-treated BD collection tubes (Becton
Dickson 365974) with glass capillaries. These bleeds were carried out at 15, 30, 60, and 90 min-
utes post injection. The collected blood was spun down in a refrigerated centrifuge at 1500g for
15 minutes. The plasma was extracted from the resulting supernatnate and stored at -80C until
quantification. The measurement of the blood ethanol content of the plasma was performed using
an Analox AM1 alcohol analyzer (Analox Instruments Ltd, UK).
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4.2.11 Light-Dark (LD) Box Testing
To begin, the mice were habituated to the testing room for 1 hour prior to the testing. Following
habituation, the mice were individually placed locomotor boxes with the dark side insert installed
(Med Associates, ENV-515). This insert occupies exactly half of the total box area and it contains a
small hole in the middle to allow free passage between the ’dark’ side and the ’light’ side. A higher
output 180mA stimulation bulb is used to produce a brighter open chamber that the mice perceive
as a greater risk of exposure to potential predators, which produces a higher level of anxiety in the
’light’ side. The mice were placed and released into the testing field by placing the mouse such that
head of the mouse was positioned just inside the entry to the ’dark’ side while the rest of the body
was placed into the ’light’ side of the chamber. The mice were then allowed to freely roam the
testing area for a single 10-minute trial, which is split into two 5-minute bins. The Med Associates
software utilized 16 infrared beam breaks to track the time spent and the distance traveled in each
side of the testing area. Percent time spent and in the dark and percent time spent in the light were
calculated and total locomotor distance traveled was documented. The analysis only considered
first 5 minute bin and Student’s t-testing to compare the Cre+ knockout mice against the Cre-
control mice.
4.2.12 Antibodies and Primers
Antibodies utilized for immunofluorescence studies:
Primary: anti-NDRG1 (1:500, Abcam, ab63989), anti-CNP [11-5B] (1:400, Abcam, ab6319),
anti-NeuN Antibody [A60] (1:500, Millipore, MAB377).
Secondary: AlexaFluor 488 anti-mouse IgG1 (1:1000, ThermoFisher, A-2112), AlexaFluor
568 anti-rabbit (1:500, ThermoFisher, A-11036)
Antibodies utilized for Western blotting studies:
Primary: anti-NDRG1 (1:1000, Abcam, ab124689), anti-MBP (1:1000, Abcam, ab7349),
anti-GAPDH [6C5] (1:7500,Millipore, MAB374).
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Secondary: 680LT Mouse IgG1 (1:50000; LiCor #926-68050), 800CW Rabbit (1:30000;
LiCor #926-32211), 800CW Rat (1:30000; LiCor #926-32219), 800CW Mouse IgG2a (1:30000;
LiCor #926-32351)
4.2.13 Microscopy
All confocal images were taken with the LSM710 using a 63X oil objective, at a scan area
and an airy unit equal to 1. Additional validation of cell-type localization images were performed
on a Zeiss IM inverted microscope using a 40X water objective or 10X air objective and a Retiga
2000R CCD camera (Qimaging, USA).
4.2.14 Mechanical Sensitivity
30 minutes prior to testing, the mice were placed in a Plexiglas cage with mesh metal flooring
and allowed to acclimate. A series of von Frey filaments (Stoelting, Wood Dale, IL) with loga-
rithmically incremental stiffness ranging from 2.83 to 5.88 grams of force. The filaments were
applied to the directly onto the paw and pushed until the filament bends and then held for 2-3 sec-
onds. If there is no paw withdrawal response to the initially selected filament, a thicker filament
corresponding was then applied. If there was a paw withdrawal event, the next weaker stimulus
filament was then tested. The stimulation of the same intensity was applied 5 times to the hind paw
at intervals of a few seconds. The mechanical threshold was recorded as Log10 of [force in (mg)]
for the force of the Von Frey filament that elicited an animal reaction, such as: paw withdrawal,
licking or shaking. This assay was performed by Dr. Wisam Toma of the laboratory of Dr. Imad
Damaj.
4.2.15 Thermal Sensitivity
Testing for thermal sensitivities utilized the acetone test and the tail flick assay. In brief, the
acetone test involves squirting 20uL of acetone onto the left and right hind paws. The number of
seconds spent licking the paws over the course of 1 minute. The average of the left and the right
paws are then taken for the comparison. The tail flick assay involved placing the tail of a mouse in
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a water bath at 50C. The time until the mouse ’flicks’ its tail out of the heated water is recorded in
seconds. This assay was performed by Dr. Wisam Toma of the laboratory of Dr. Imad Damaj.
4.2.16 Nerve Conduction Velocity Testing
Nerve conduction velocity (NCV) and sensory nerve action potential amplitudes (SNAP) of
the caudal nerve were recorded with a PowerLab 4/35 electromyography system (ADInstruments,
Inc, CO, USA). This test measures amplitude and latency of the evoked response, which is used to
calculate nerve conduction velocity. Anesthesia was carried out using a VetFlo anesthesia machine,
(KentScientific, CT, USA) induced in a chamber with 4% isoflurane carried in oxygen followed by
2.5% isoflurane by nose cone for maintenance during the procedure. A couple of needle record-
ing electrodes (cathode and anode) were inserted 5 mm distal from the base of the tail, and the
stimulating electrodes 5.0 cm apart from the recording points (distance measured from cathode
to cathode) with a ground electrode in-between the stimulation and recording electrodes. The
nerve was stimulated with single square-wave pulses of 0.1 ms duration at 7 mA, and a repeat
rate of 1Hz. The neurophysiological measures were conducted under standard conditions in a
temperature-controlled room. NCV was calculated by dividing the distance between the recording
and stimulating electrodes (0.05 m) by the latency between the stimulus artifact and the onset of
the first peak of the elicited action potential latency of the sensory nerve action potential. NCV
was measured in m/s, and SNAP in uV. This assay was performed by Dr. Wisam Toma of the
laboratory of Dr. Imad Damaj.
4.2.17 Rotarod Testing
The mice were habituated the the testing room for 1 hour prior to the start of the experiment.
The testing was performed on Rotarod motor performance testing apparatus. All testing utilized
the Fixed Speed Rotarod Rate (FSRR) protocol. The FSRR protocol involves placing the mice
onto the spinning rod while it was rotating at 10 RPM. Once the mouse has been released, the test
begins. The software records the time until the mouse either falls off of the rotor or the mouse
clings to the rotor and is completely rotated in a circle. The time (in seconds) at which either of
these two stop points occurs is the recorded measure. The trial will run for up to 300 seconds, at
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this point the trial is complete and the recorded measure will be 300 seconds. On all testing days,
each mouse was tested in 3 separate trials.
4.2.18 Paclitaxel Sensitivity Study
Prior to delivery of tamoxifen to induce KO of Ndrg1, mice were measured for baseline me-
chanical sensitivity. Following this baseline, the mice were split into one of the following treatment
groups: Cre+/Paclitaxel, Cre+/Vehicle, Cre-/Paclitaxel, Cre-/Vehicle. Starting the following day,
all mice began to receive the standard dosing of Tamoxifen to induce Cre recombinase in the Cre+
animals ( 75mg/kg, i.p, every other day for 5 days (3 total treatments)). After the day after the 3rd
and final Tamoxifen treatment, the mice were again tested with Von Frey Filaments. Following
the second baseline, the Paclitaxel treatment regiment was started. In this protocol, a low dose of
Paclitaxel (1 mg/kg, i.p.) is administered every other day for a total of 4 treatments. The day after
the 2nd Paclitaxel injection, the mechanical sensitivity of the mice was recorded again. Two days
after the final injection, the mice were again testing for mechanical sensitivity using the Von Frey
filaments. The mechanical sensitivity testing then continued once a week for one month.
4.2.19 High Dose Ethanol Neuropathy Study
Similar in design to the Paclitaxel study, prior to delivery of tamoxifen to induce KO of
Ndrg1, mice were measured for baseline mechanical sensitivity. Following this baseline, the mice
were split into one of the following treatment groups: Cre+/Ethanol, Cre+/Vehicle, Cre-/Ethanol,
Cre-/Vehicle. Starting the following day, all mice began to receive the standard dosing of Tamox-
ifen to induce Cre recombinase in the Cre+ animals ( 75mg/kg, i.p., every other day for 5 days (3
total treatments)). After the day after the 3rd and final Tamoxifen treatment, the mice were again
tested with Von Frey Filaments. Following the second baseline, the ethanol treatment regiment was
started. In this protocol, a high dose of ethanol (3.8 g/kg, i.p.) is administered every other day for a
total of 4 treatments. The day after the 2nd ethanol injection, the mechanical sensitivity of the mice
was recorded again. Two days after the final injection, the mice were again tested for mechanical
sensitivity using the Von Frey filaments. The mechanical sensitivity testing then continued once a
week for one month.
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4.3 Results
4.3.1 Validation of the Ndrg1 Deletion in Myelinating Cells
By 4 weeks post-Tamoxifen administration, there a robust knockout of Ndrg1 in the mPFC.
We observed a very dramatic reduction in immunosignal for NDRG1 in both male and female
Cre+ PCNdrg1 mice (see Figure 4.2). Furthermore, when Ndrg1 is co-stained with oligodendro-
cyte and myelin process marker, CNPase, we confirm that the loss of both cellular and myelin
process NDRG1 by 6 weeks post-Tamoxifen (see Figure 4.3). The ’speckling’ pattern of NDRG1
staining that is observed in the KO mice (see Figure 4.3C) is non-specific staining. We suggest
that the polyclonal anti-NDRG1 antibody (ab639890) utilized for IHC in this chapter was likely
responsible, as this ’speckling’ staining pattern was not observed in the IHC presented in Chapter 3
that was performed with the monoclonal anti-NDRG1 (ab124689) (see Figure 3.3).
Figure 4.2: IHC validation of KO in male and female PCNdrg1 mice, 4 weeks post-Tamoxifen.
Orange arrows indicates the horn of the corpus callosum, as shown on the rightmost image. All
slices received the same IHC staining protocol. All images were taken at the same microscope
illumination intensity and camera exposure time on a 10X air objective with a Zeiss IM micrscope.
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Figure 4.3: Confocal validation of KO of NDRG1 in oligodendrocytes and myelin PCNdrg1 mice,
male mouse 6 weeks post-Tamoxifen. 63X microscopy image of oligodendrocytes and myelin
processes in the mPFC (top shows Cre- control, bottom shows Cre+ knockout): a) DAPI b) CNPase
c) NDRG1 d) Composite overlay
Western blotting of the frontal cortex dissections at both 1 month and 6 months post-Tamoxifen
revealed a dramatic reduction of total NDRG1 protein levels. The 1 month and the 6 month data
were analyzed separately and initial analyses were conducted with a 2-way ANOVA model that
considered genotype and sex. The sciatic nerve tissue and the frontal cortex tissue were harvested
from the group of experimental mice. There were 20 total mice utilized in the presented study
(N=5 per sex / per genotype).
In the frontal cortex, at one month post KO, the 2-way ANOVA revealed a main effect of
genotype (F = 231.0, P = 6.27E-11), but no effect or interaction with sex was present (F = 0.028, P
= .869). Thus, we collapsed the sexes and performed a simple Student’s t-test. At one month, there
was a 90% reduction in total Ndrg1 signal (T = 16.093, P = 2.15E-08). Furthermore, we found that
both PLP and MBP (T = 4.007, P = 0.0018) levels were significantly downregulated in the frontal
cortex 1 month following deletion (see Figure 4.4)
At 6 months post KO in the frontal cortex, the 2-way ANOVA revealed a main effect of geno-
type (F = 39.775, P = 1.04E-05), but no effect or interaction with sex was present (F = 0.237,
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P = .633). Thus, we collapsed the sexes and performed a simple Student’s t-test. There was a
65% reduction in immunosignal (T = 6.592, P = 9.34E-06) at the 6 month time point. While a
very significant reduction was maintained for at least 6 months, there might to be some recovery
of NDRG1 signal in oligodendrocytes at 6 months post-tamoxifen compared to just 1 month (see
Figure 4.4). Likewise, we found that MBP levels (T = 2.598, P = 0.0184) in the frontal cortex were
still decreased at 6 months post KO, while the PLP levels (T = 0.566, P = 0.580) had recovered to
normal levels by the 6-month time point (see Figure 4.4).
Figure 4.4: Western blot analysis of frontal lobes after conditional deletion of Ndrg1 in oligoden-
drocytes at 1 month (top) and 6 month (bottom) time points for NDRG1, MBP, and PLP1. Panels
on right display mean expression for each target was normalized to GAPDH and to the wild type
controls (error bars = SE) (bottom). N = 5 per genotype / per sex. Student’s t-test were used for
statistical analysis. (*, P < 0.05; **, P < 0.005 ; ***, p < 0.0001)
Similarly, western blotting of the sciatic nerve dissections at both 1 month and 6 months
post-Tamoxifen revealed a dramatic reduction of total NDRG1 protein levels (see Figure 4.5).
At one month, the there was a 50% reduction (T = 7.038. P = 5.167E-06) in total Ndrg1 signal,
while there was still a 40% reduction (T = 3.328, P = 0.00574) in immunosignal at the 6 month
time-point. While a very significant reduction was maintained for at least 6 months, but there might
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to be some recovery of NDRG1 signal at 6 months post-tamoxifen compared to just 1 month (see
Figure 4.5). Likewise, we found no different in total levels at either 1 or 6 months post-Tamoxifen,
but there is a trend towards decreased levels of total MBP (T = 1.309, P = 0.209) in the sciatic
nerve as more time passes post-Tamoxifen (see Figure 4.5).
Figure 4.5: Western blot validation of KO of NDRG1 and MBP levels in peripheral nerve tis-
sue. Left side of panel shows the total NDRG1 signal at 1 month (top) and 6 months (bottom)
post-Tamoxifen. The total signal for MBP is displayed in the same fashion on the right side of the
panel. Student’s t-test (** P < 0.01)
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4.4 Control Experiments
We ran multiple control studies to characterize whether tamoxifen-regulated Ndrg1 deletion
caused any changes in basal locomotor or anxiety-like behaviors, ethanol pharmacokinetics or
tastant preferences, since such confounders could obscure interpretation of results for ethanol be-
havioral responses. For these experiments, we utilized a single cohort of male and female mice (N
= 5 per sex / per genotype). Statistical analysis was performed with Student’s t-test for compar-
ison between the knockout and control genotypes. First, we found no differences in anxiety-like
behavior (time in the light: T = 0.35, P = 0.704; time in the dark: T = -0.358, P = 0.724) or total
locomotor activity in the light-dark (LD) box (see Figure 4.6A, B, C). It is notable here is the be-
ginning of a trend towards decreased total locomotor distance traveled (T = 1.837, P = 0.0842)in
the knockout (Cre+) mice, but there was no significant differences between the knockout and the
control mice at 2 months post-Tamoxifen. Next, we observed no alteration in perception of bitter
(quinine) and sweet (saccharin) tastants between the KO and control mice. Finally, we found no
differences in the pharmacokinetics of ethanol metabolism (F = 0.035, P = 0.873) following a high
dose of ethanol (see Figure 4.6).
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Figure 4.6: Control experiments for PCNdrg1 KO mouse line. (A) Time spent in the light side of
the LD chamber (B) Time spent in the dark side of the LD chamber (C) Total locomotor activity
recorded over the sesssion (D) Preference for quinine adulterated water relative to plain tap water
(E) Preference for saccharin sweetened water to plain tap water. # denotes a suggestive P-value <
0.1.
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Figure 4.7: Ethanol pharmacokinetics: BEC time course following 4 g/kg of acute ethanol. Sta-
tistical analysis performed using linear mixed models. BEC was recorded at the following time
points post-injection: 15, 30, 60, and 90 minutes. 2-way linear mixed model statistics were used.
4.5 Deletion of Ndrg1 in Myelinating Cells Alters Ethanol-Related Behav-
iors
We evaluated the voluntary ethanol consumption of ethanol when presented with a 3-bottle
choice drinking study for 5 total weeks. The study was well powered by combined two cohorts
of PCNdrg1 mice (N = 10 - 16 per sex / per genotype). First, a simple Student’s t-test revealed
a very significant difference between the amount of ethanol consumed in female and male mice
collapsed across genotypes. As expected, we found that the females, on average, consumed 37%
(P < 0.001) more total ethanol than males per drinking day Figure 4.8A). Due to this sex effect, the
following drinking related statistics and findings with regard to the Ndrg1 deletion will consider
sex separately. We found no significant alterations in average daily intake of ethanol across the
entire 5 week study, but there was a suggestion of an increase total ethanol consumption (P =
0.054) in the male Cre+ mice (see Figure 4.8B).
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Figure 4.8: Comparison of male and female average daily ethanol (g/kg) in 3-bottle choice drink-
ing. (A) Comparison of daily average intake all male and female mice, without considering geno-
type. (B) Comparison of daily average intake in Cre+ KO mice and Cre- control mice, separated
by sex. Student’s t-test (# P < 0.l; ** P < 0.001)
Further 2-way ANOVA analysis considered the average daily intake by bottle (15% vs. 30%
consumed) and genotype for each sex separately. This statistical model revealed both male and
female sex-specific alterations in drinking (see Figure 4.9A). Following post-hoc comparison with
Tukey’s HSD, we observed a significant decrease in 30% consumption in female Cre+ knockout
mice (P < 0.05) relative to control, while an intake in 15% preference was observed in the male
Cre+ knockout mice (P < 0.05) relative to control (see Figure 4.9A).
To analyze the alterations in drinking behavior that occur over the course of the 5 week drink-
ing study, we utilized linear mixed model statistics. Here, we investigated total ethanol preference
at the weekly level using a 3-way mixed model that considers the weekly preference averages,
the genotype, and the sex of the mice. The individual mice are set as the error parameter, since
each mouse is measured at every reading throughout the study. Our 3-way mixed model revealed a
significant main effect of genotype (F=6.701, P = 0.00964) and week (F = 185.074, P < 2.2E-16),
with no other effects or interactions. Therefore, we collapsed the sexes and further analyzed the
data with a 2-way mixed model the only considered the week and the genotype. Here we found
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that the Cre+ knockout mice maintained a significantly higher preference (F = 6.117, P = 0.0134)
for ethanol over the duration of the 5 week study (see Figure 4.9B).
Figure 4.9: Average daily ethanol intake and average preference for ethanol by each drinking
week. (A) Average daily ethanol intake for 3-bottle choice drinking, per alcohol concentration
(15% or 30%) and sex. Left: Females. Right: Males (2- way ANOVA, * P < 0.05). (B) Weekly
average ethanol preference by genotype. Linear mixed model statistics. Main effect of genotype
highlighted by asterisk bar (P = 0.0134).
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We investigated the effect of Ndrg1 deletion on acute sensitivity to ethanol using the LORR
protocol. We used mice of both sexes (N = 5 per genotype / per sex). Analysis was performed
with Student’s t-test. We found that neither the onset to LORR or the duration of LORR were
significantly altered by Ndrg1 deletion (see Figure 4.10A and Figure 4.10B). There was no effect
of sex on either metric (not shown), so both sexes were collapsed to increase power. This resulted
in a suggestion of a decrease in the onset time (p < 0.1) (see Figure 4.10A).
Figure 4.10: Loss of Righting Reflex (LORR) onset and duration. (A) time in seconds until the
onset of LORR. (B) time in minutes until recovery of righting reflex. Student’s t-test statistics (# P
< 0.1)
4.6 Deletion of Ndrg1 Results in Peripheral Nerve Dysfunction
4.6.1 Deletion of Ndrg1 Leads to Long-Lasting Mechanical Hypersensitivity
Selective deletion of Ndrg1 in myelinating cells produced long-lasting mechanical hypersen-
sitivity as measured by Von Frey filaments. To begin, mice of both sexes (N = 6 Cre-; N = 8 Cre+)
were tested for baseline mechanical sensitivity before Tamoxifen administration. Sexes were col-
lapsed and simple Student’s t-tests are used for statistical analysis. As shown in Figure 4.11, there
was no difference between the mechanical thresholds for between the two genotypes (P > 0.5). By
as little as two weeks post-Tamoxifen, there was development of significant hypersensitivity (T
= 2.931, P = 0.0199) (see Figure 4.12A). By 2 months post-Tamoxifen, the hypersensitivity was
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increased beyond the minimal detectable filament (T = 4.332, P = 0.00675) (see Figure 4.12B). Fur-
thermore, this hypersensitivity is very long lived, as the knockout mice show hypersensitivity still
at the minimal detectable filament force (T = 4.899, P = 0.0060) at least 8 months post-Tamoxifen
(see Figure 4.13).
Figure 4.11: Baseline measurement of Cre+knockout mice and Cre- control mice of mixed sexes
before the administration of Tamoxifen. Student’s t-test (P > 0.5).
Figure 4.12: Time course for development of altered mechanical sensitivity following deletion of
Ndrg1. (A) 2 weeks post-Tamoxifen. (B) 8 weeks post-Tamoxifen. Student’s t-test (** P < 0.05;
*** P < 0.01).
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Figure 4.13: Heightened mechanical sensitivity is long lasting after Ndrg1 deletion. Filament force
measurements 8 months post-Tamoxifen. Student’s t-test (*** P < 0.01).
Figure 4.14: Thermal sensitivity testing of PCNdrg1 KO mice 3 months after Ndrg1 deletion. (A)
Acetone testing for cold sensitivity: average time spent licking paw after 20uL acetone on hind
paws. (B) Tail flick assay for hot sensitivity: average latency until tail is withdrawn from 50C
water bath. (Student’s t-test, ** P < 0.005)
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4.6.2 Homozygous Deletion of Ndrg1 Causes Alterations of Thermal Sensitivity
Using the same cohort of mice from the above mechanical sensitivity study (see Figure 4.12),
we tested for cold and thermal sensitivities at 3 months post-Tamoxifen administration. We found
that Cre+ knockout mice spent significantly more time licking their paws after the application of
acetone (T = -3.947, P = 0.000454), suggested increased sensitivity to cold stimulus (see Fig-
ure 4.14A). Conversely, we observed no differences (T = 0.0634, P = 0.951) in the latency to flick
the tail out of a heated water bath between Cre+ and Cre- mice (see Figure 4.14B).
4.6.3 Heterozygous Deletion of Ndrg1 does not Alter Sensitivity
In order to assess a possible gene dosage effect for Ndrg1 loss-induced sensory modality
changes, we studied heterozygous Ndrg1 mice having one intact gene. We utilized both sexes of
homozygous and heterozygous mice in this study. Statistical analysis was performed with 3-way
linear mixed model that considered genotype (Cre+/Cre-), date measured, and group (Full KO or
HET). While main effects of genotype and date measured were identified, we found no differ-
ences between heterozygous Ndrg1 deleted mice with respect to mechanical or cold sensitivity
(see Figure 4.15). The only group of mice that diverged from the Cre- control groups was the
full homozygous deletion of Ndrg1, as noted in Figure 4.15. It is worth noting that all groups of
mice developed some sensitivity to the assays due to over testing, which can result from too many
mechanical measures in a short period of time. Regardless of this over testing effect, the homozy-
gous Ndrg1 deletion (Cre+/full KO) was the only group that significantly diverged from the control
groups.
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Figure 4.15: Tracking of mechanical and cold sensitivity over time in heterozygous Ndrg1 KO
mice. (A) Time course of development of mechanical sensitivity in HET and KO mice. Linear
Mixed Model statistics, asterisks(*) at a measurement day indicates Cre+/KO was significantly
different from at least one of the other three groupings (Tukey’s adjusted p-value < 0.05). (B) Time
course of development of cold sensitivity in HET and KO mice. Linear Mixed Model statistics,
asterisks(*) at a measurement day indicates Cre+/KO was significantly different from at least one
of the other three groupings (Tukey’s adjusted p-value < 0.05). No other groupings (Cre-/KO,
Cre+/HET, Cre-/HET) were significantly different from each other at any measurement day.
4.6.4 Ndrg1 Deletion Results in Motor Skill Deficits, but Not Motor Learning
Since prior studies by other investigators have documented motor deficits with prolonged
Ndrg1 deletions in animal models (Okuda et al. 2004; Chandler et al. 2013), we commenced
studies on these aspects of peripheral nerve function. Beginning at 2 months post-Tamoxifen,
we began testing the Cre+ knockout mice for motor performance using a Romex rotarod machine.
This experiment was conducted using the same cohort of mice that underwent the thermal sensi-
tivity studies described above. At the first testing day, the Cre+ knockout mice remained on the
rotarod for significantly less time than controls (Figure 4.16A). Retesting the same group of mice
2 weeks later revealed that both genotypes improved in their ability to stay on the rotarod for a
longer amount of time. Interesting, the Cre+ show a larger degree of improvement relative to the
Cre- control (Figure 4.16B). At the 3rd and final testing day, we found no additional improvement
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in the Cre- group, but we did see that the Cre+ knockout mice continued to improve compared to
their 8 week time point, and had no significant difference from the Cre- controls (Figure 4.16C).
Figure 4.16: Performance on a fixed speed Rotarod protocol in KO mice over time. The Rotarod
was tested at the following time points post-Tamoxifen: (A) 8 weeks, (B) 10 weeks, (C) 12 weeks.
Linear Mixed Model statistics, asterisks (*) note relevant post-hoc contrasts (Tukey’s adjusted
p-value < .05)
4.6.5 Ndrg Deletion Adversely Affects Peripheral Nerve Conduction and Velocity
We found that both velocity and amplitude of peripheral nerve conduction was decreased by 6
months post-tamoxifen. We recorded the nerve conduction velocity of the cohort of mice that was
tested for thermal sensitivities and Rotarod performance as described above. Statistical analysis
was performed using Student’s t-test. The sexes are analyzed separately as well as collapsed. As
this 6 month time point, the decrease was found in both male and female mice, and in both cases we
see a much greater decrease in amplitude than noted for the velocity measurements (Figure 4.17).
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Figure 4.17: Nerve conduction and velocity testing 6 months port-Tamoxifen. Top row: Am-
plitude. Bottom row: Velocity. Left panel (males), middle panel (females), right panel (sexes
collapsed). Student’s t-tests (** P < 0.01; *** P < 0.001)
4.6.6 Sensitivity to Severity of Paclitaxel-Induced Neuropathies is Enhanced byNdrg dele-
tion
To directly prove that loss of Ndrg1 expression altered the sensitivity to Paclitaxel-induced
peripheral neuropathy, we employed a low dose Paclitaxel treatment that caused a submaximal and
reversible increase in mechanical hypersensitivity. Here we utilized PCNdrg1 mice of both sexes,
with the intent of collapsing sexes due to low N (N = 3 per sex / per genotype / per treatment). The
experiment was analyzed with a 3-may linear mixed model that considered genotype (Cre+/Cre-),
date measured, and treatment (Paclitaxel or saline). The low dose Paclitaxel study provided several
pieces of information, including a clearer look at the time course for the development of mechanical
sensitivity following Ndrg1 deletion. First, we found no changes of the mechanical sensitivity of
Cre- mice that received vehicle, establishing that the mice were not over-tested (see Figure 4.18,
dashed blue line). As expected, based on the literature, we observed a transient development
of hypersensitivity in Cre- control mice that received low dose Paclitaxel that resolved by the
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end of the study (see Figure 4.18, solid blue line) . Regarding the time to develop dysfunction
following Ndrg1 deletion induction, we found that 1 week post-tamoxifen was the earliest we
detected significant hypersensitivity in the vehicle treated Cre+ mice (Figure 4.18, dashed red line,
d15). The vehicle treated Ndrg1 deletion mice reached the floor of the Von Frey Filament testing
by day 25, 2 weeks following the end of Tamoxifen treatment. In contrast, the Cre+ knockout mice
that received low dose Paclitaxel began to show significant signs of sensitivity immediately after
just 2 of the 4 doses of Paclitaxel (see Figure 4.18, solid red line, d11). These Cre+ Paclitaxel
treated mice reach the floor of the Von Frey Filament testing by the day immediately after the 4th
Paclitaxel injection (see Figure 4.18, solid red line, d15).
Figure 4.18: Tracking of mechanical sensitivity over time following Tamoxifen and low-dose Pa-
clitaxel. The delivery date of the Tamoxifen and the measurement points are noted in the boxes
at the top of the plot. 3-way linear mixed model statistics. Post-hoc testing was performed with
Tukey’s HSD. Relevant contrasts are highlighted in a-d. (a) After 2 of 4 PAC doses, the PAC
treated Cre+ mice are significantly more sensitive than saline-treated Cre+ mice (P < 0.001). (b)
After 4 of 4 PAC doses, the the PAC treated Cre+ mice are still significantly more sensitive than
saline-treated Cre+ mice (P < 0.05). (c) After 4 of 4 PAC doses, the the PAC treated Cre- mice
are significantly more sensitive than saline-treated Cre- mice (P < 0.05). (d) 1 week after com-
pleting of PAC treatment, the the PAC treated Cre- mice are still significantly more sensitive than
saline-treated Cre- mice (P < 0.05). By this time point, both Cre+ treatment group were at the floor
of the mechancial senstivity threshold for testing.
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4.6.7 Repeated High Doses of Ethanol do not Alter the Development of Mechanical or Cold
Sensitivity Following Deletion of Ndrg1
Given the augmentation of Paclitaxel-induced mechanical hypersensitivity by Ndrg1 deletion,
we sought to determine if the gene might also play a role in one of the most frequent causes
of induced peripheral neuropathy – AUD. We thus conducted a pilot study similar in design to
the low-dose Paclitaxel experiment described above. We assessed both acetone-induced cold hy-
persensitivity and mechanical hypersensitivity. The experiment used male mice only (N = 5 per
genotype / per treatment) and we utilized a 3-way linear mixed model that considered genotype
(Cre+/Cre-), date measured, and treatment (etOH or saline). We uncovered significant main effects
of genotype (F = 39.63, P = 3.064E-10) and date measured (F = 194.35, P < 2.2E-16), but there
was no effect of treatment group (F = 0.041, P = 0.841). We found no changes of the mechani-
cal or cold sensitivity of Cre- mice that received only vehicle, establishing that the mice were not
over-tested (see Figure 4.19, dashed blue line). However, we also did not observe any alterations
in the ethanol treated Cre- control group in either cold or mechanical sensitivity over the course of
the study (see Figure 4.19, solid blue line), suggesting a lack of ethanol-induced peripheral nerve
dysfunction at this ethanol dose and time regimen. Following Cre induction by Tamoxifen, both
vehicle- and ethanol-treated mice developed cold or mechanical hypersensitivity at 2 weeks post
Tamoxifen ( Figure 4.19, dashed and solid red line). Additionally, all Cre+ mice reached the floor
of the Von Frey Filament testing by just 2 weeks following the end of Tamoxifen treatment.
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Figure 4.19: Tracking of mechanical and cold sensitivity over time following repeated high doses
of following deletion of Ndrg1. (A) Tracking of mechanical sensitivity over time. (B) Tracking
of cold sensitivity over time. Tamoxifen treatment began on measurement day 1 as indicated in
(B). Linear mixed model statistics. * highlights the significant main effects of genotype and date
measured. (* P, < 0.0001)
4.7 Discussion
We have identified numerous consequences that arise from deletion of Ndrg1 in myelinating
cells of the central or peripheral nervous system. We found changes in drinking behaviors and pro-
vided evidence that acute sensitivity is being subtly modulated by Ndrg1 deletion (see Figure 4.8
and Figure 4.9). We have strong evidence that these differences in ethanol behaviors were not due
to a typical experimental confounders (see Figure 4.6). We observed a very rapid increase in the
mechanical sensitivity of the hind paws of KO mice (see Figure 4.12). This increased sensitivity is
very long-lived and does not recover for at least 8 months following KO (see Figure 4.13). Other
signs of nerve dysfunction, such as cold sensitivity, also developed rapidly while others, such as
tail flick latency, did not (see Figure 4.14). Additionally, Cre+ KO mice had significantly decreased
velocity and amplitude of nerve conduction by at least 6 months post-KO (see Figure 4.17). We
found that mice that were heterozygous for floxed-Ndrg1 mice did not show any signs of increased
mechanical or cold sensitivity following Tamoxifen (see Figure 4.15). Importantly, we provided
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fundamental evidence that levels of nerve Ndrg1 are inversely correlated with the level of nerve
dysfunction observed following Paclitaxel treatment (see Figure 4.18). Finally, we did not find any
correlation between the levels of nerve Ndrg1 and development of nerve dysfunction following
repeated high doses of ethanol (see Figure 4.19).
It is worth noting that the nerve conduction velocity testing only recorded and measured the
latency from the initial stimulus to the 1st peak. When measuring nerve conduction velocity,
there are two peaks that can be measured. The first peak that arrives is from signal conduction
along myelinated fibers, while the slower second peak is from signal conduction along unmyeli-
nated fibers. Given the very rapid onset of mechanical sensitivity that follows Ndrg1 deletion
occurs well before any visible motor defects, it is possible that Ndrg1 deletion is occurring in the
unmyelinated Schwann cells which support unmyelinated fibers. Given that Von Frey filaments
measure mechancial nocieption and that unmyelinated C fibers are the primary sensory receptor
for mechanical stimulation, it is possible that the rapid onset of mechanical sensitivity is driven by
dysfunction of C fibers soon after Ndrg1 deletion. It would be very worthwhile to follow up with
additional nerve conduction velocity that measures both peaks. If a more rapid degradation of the
second peak occurs, then Ndrg1 deletion is vital for the function for both myelinated nerves and
unmyelinated sensory fibers.
Remarkably, the alterations in the consumption patterns of 15% and 30% ethanol consumption
are strikingly similar to the lentiviral pilot data (see Figure 2.6). There is evidence that mPFC
Ndrg1 levels could in fact be the main driver of ethanol sensitivity and concentration preference,
but this mouse model is not able to answer this question since the knockout is global in both the
CNS and the PNS. In order to have this fine control, an injection of a MBP-Cre virus into the
mPFC of floxed-Ndrg1 mice would, for example, be able to provide the necessary localization.
Additionally, it is wholly possible that the peripheral effects of Ndrg1 deletion could alter ethanol
drinking through other means. If the mechanical sensitivity values are reflective of a pain-like
state, there is evidence that male mice will escalate their ethanol consumption while female mice
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do not alter their ethanol behaviors in response to a painful stimulus, such as CFA injection into
hind paws (Yu et al. 2019).
We found that mechanical sensitivity develops very rapidly following the knockout of Ndrg1,
suggesting that continuous expression of Ndrg1 is necessary for the function of the peripheral
nervous system at least in terms of this sensory modality (see Figure 4.12). It is also interesting
that we begin to see some peripheral nerve recovery of Ndrg1 at 6 months post-tamoxifen, but there
is no recovery of the deletion-induced mechanical hypersensitivity at 8 months. This suggests that
although there are adequate levels of myelin protein in the peripheral nerve (as Ndrg1 deletion did
not alter peripheral MBP protein expression – Figure 4.5), the function or the structure of myelin
could have been perturbed sufficiently without Ndrg1 expression that partial reestablishment of
Ndrg1 expression could not rescue nerve function over this time course. Perhaps this is because
the axon suffers un-repairable damage without some potential tropic effects of Ndrg1 contained
in the adjacent myelin processes. As noted in the literature, Ndrg1 clearly affected sensory and
motor function in the PNS (Okuda et al. 2004). However, the fact that our Cre+ knockout mice
were able to drastically improve their Rotarod performance suggests that motor skill learning is
still intact (see Figure 4.16). Further studies into motor skill versus function could help establish
more precise knowledge of the specific functions of Ndrg1.
Importantly, our work with low dose Paclitaxel administered during the active deletion of
Ndrg1 demonstrates the basal levels of nerve Ndrg1 are essential for protection of the myelin and
the nerve following a known peripherally toxic agent. This work assumes a fairly linear falloff
of NDRG1 levels over the time post-tamoxifen. It also does not provide a steady reduced level
of NDRG1 protein. Due to these assumptions and limitations, there would be an advantage to
running this experiment with PCNdrg1 HET mice. Assuming that the HET mice do in fact have
lower levels of NDRG1 protein, we would expect the HET mice to be more sensitive to Paclitaxel
than the Cre+ vehicle-treated mice. Another point is the repeated testing of the mice in the nerve
dysfunction assays. It is known that over testing of the sensory perception tasks can lead to altered
and increased sensitivity. This can affect the measurements and confound the results. We expe-
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rienced this with the HET experiment, as the mice saw much testing over a short period of time
(acetone/Von Frey/Rotarod). There is the possibility that is occurred in our low dose Paclitaxel
experiment and high dose ethanol study. However, the stability of the Cre- vehicle-treated groups
over the course of that study suggests that the mice were not over-tested in the same manner as the
HET data, where all mice increased their sensitivity over the course of the study.
While there was no short term effect of repeated high doses of ethanol on the development
of mechanical and cold sensitivity, this does not mean there was no deleterious effect from these
high dose ethanol exposures. Given that we do not see alterations in the nerve conduction and
velocity of Cre+ knockout mice until 6 months after Ndrg1 deletion, it would be worth taking sev-
eral long-term measurements of mice that received the high doses ethanol. Perhaps nerve testing
and cold sensitivity testing at 6 months would reveal larger deficits in Cre+ knockout mice that
received the ethanol exposures. Additionally, it could be that too few ethanol injections were uti-
lized to drive any acute toxic effects from the current regiment. It might also be wise to deliver
the repeated doses of ethanol 2-3 months post-Tamoxifen, when the knockout is more robust and
major motor deficits are beginning to occur. At that time, the already damaged peripheral nervous
may have a much stronger response to the noxious levels of ethanol. Such future studies could
have an important clinical impact by identification of a possible risk factor and mechanistic target
(Ndrg1) for ethanol-induced peripheral neuropathy, which together with diabetes-related periph-
eral neuropathy, is one of the largest causes for clinical presentation of peripheral nerve disease.
Due to the large difference in the severity of PNS and CNS dysfunction following Ndrg1
deletion, further studies into the transcriptome response differences between the CNS and PNS
were planned. Tissue from both the mPFC and the Sciatic nerve were isolated and mRNA was
extracted. We sought to investigate these differences using the latest generation of microarray
technology (ClariomS Mouse Assay) from Affymetrix/Thermo-Fisher. In order to fully utlize the
power of this microarray technology, a novel differential gene expression algorithm and package,
GCSscore, was created and validated. The details of the algorithm/package and its validation are
the subject of Chapter 5.
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Chapter 5
GCSscore: a differential expression algorithm
5.1 Introduction
Despite the advent of RNAseq for transcriptomics analysis, microarrays continue to be widely
used with an average of over 7000 PubMed citations per year in 2015-2019. A major commercial
platform for microarray analysis, produced originally by Affymetrix and now by ThermoFisher,
utilizes collections of oligonucleotides distributed across cognate genes to probe RNA expres-
sion by hybridization. Popular analysis methods for oligonucleotide arrays, such as the Robust
Multiarray Analysis (RMA) method, produce expression values for given genes/transcripts/exons
by summarizing hybridization intensities across all corresponding oligonucleotides (Irizarry et al.
2003). Since expression “differences” rather than absolute expression levels are generally the
goal in microarray studies, our laboratory previously developed the S-score algorithm for analysis
of Affymetrix oligonucleotide microarrays for detecting significant expression changes between
paired samples (Zhang et al. 2002). This entailed comparing individual oligonucleotide probes
within each probeset between two samples, after applying a heteroscedastic error correction model.
The S-score method provided an easily interpretable standard normal distribution of expression dif-
ferences between two samples for a given probeset, akin to a z-score transformation. Prior work
demonstrated the advantage of the S-score method over probe summarization techniques such as
RMA for Affymetrix microarray analysis, particularly for experiments having smaller numbers of
replicates (Zhang et al. 2002; Kennedy, Archer, and Miles 2006). This advantage prompted de-
velopment of a Bioconductor R package, sscore, for application of the original S-score method on
Affymetrix microarrays (Kennedy, Archer, and Miles 2006). This algorithm has been utilized in
publications across multiple laboratories for studies based on 3’ IVT array technology (Kerns et al.
2005; Grice et al. 2007; Singh et al. 2011; Wolstenholme et al. 2011; Wolen et al. 2012; Paxson
et al. 2013; Vaart et al. 2017; Bogenpohl et al. 2019). The original S-score relies on the differ-
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ence between perfect match (PM) and cognate mismatch (MM) probes to correct for non-specific
hybridization while calculating a measure of expression difference between two samples. MM
probes were designed to capture array background noise (rawQ) and non-specific binding (NSB)
of off-target transcripts. However, MM probes were subsequently shown to be an inconsistent mea-
sure of non-specific binding (Schuster et al. 2007). While the RMA method excluded MM probe
data from the expression calculation and has come to be widely used, use of RMA summariza-
tion/normalization followed by appropriate statistical testing differential gene expression does not
utilize probe-level information as with the S-score. Since NSB signal is strongly correlated with
GC-content of the probe sequence, newer Affymetrix array technology eliminated the MM probes
and instead utilized 16,943 antigenomic probes of varying GC-content on 25-mer oligonucleotide
targets ranging from 3 (12% GC) to 25 (100 % GC) to estimate non-specific binding (Affymetrix
2005). This new technology, referred to as Whole Transcriptome (WT) arrays, allows probes to be
grouped either in Transcript Cluster IDs (TCids) for a gene-level analysis or into Probe Selection
Region IDs (PSRids) for an exon-level analysis. Subsequent arrays designs provide more detailed
measures of exon expression and transcript splicing variants, via exon-exon Junction IDS (JU-
Cids), that are on par with RNA-seq (Xu et al. 2011). These Transcriptome Assay chip types were
released for human (HTA1.0/2.0), rat (RTA1.0), and mouse (MTA1.0). This fully featured design
was further developed into the ClariomD chip type, available for human and mouse. An additional
gene-level only chip type, the ClariomS, was created using only the ten best performing probes
from each TCid present on the ClariomD/Transcriptome Assay (HTA/RTA/MTA) designs, which
will be referred to as ClariomD/XTA arrays. Unfortunately, no generations of the WT-style arrays
are compatible with the original S-score algorithm and existing sscore R package for probe-level
analysis due to lack of MM probes on the new array designs. We have therefore developed an R
package, GCSscore, with a new algorithm that enables the S-score probe-level analysis method for
the newest generation of Affymetrix/ThermoFisher Clariom-style microarrays. We have also uti-
lized updated data handling methods that improve the speed of the analysis considerably. We show
here that GCSscore performed similarly to the originally published sscore R package for older type
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microarrays (3’ IVT) and added functionality for analysis of the newest Affymetrix/Fisher microar-
ray types. Furthermore, our results suggest that use of the GCSscore package provides substantial
benefit compared to existing methods in detection of differential gene expression (DEG) on these
newer generation microarrays.
5.2 Implementation
5.2.1 Algorithm
The most fundamental change from the original algorithm is the introduction of background
correction based on the median signal of antigenomic probes having the same GC-content as a the
given PM probe, rather than relying on the cognate MM probe hybridization signal. The GCS-score
algorithm is based upon the operations in equations (1) through (3). For a given probe grouping
method, k, which is made up of N probes, the GCS-score, denoted as GCSsk, is as follows:
GCSsk =
N
∑
i=1
liB− liA
εi
√
N
(1)
ε =
√
γ2(l2iB− l2iA)+SDT 2A +SDT 2B (2)
SDT = 4∗ rawQ∗SF (3)
• liA and liB : background corrected intensities of the i-th probe pair from array A and B,
respectively.
• N = number of probes in a probesetID or transcriptclusterID
• γ = a scaler constant (γ = .1)
• SDT = 4∗ rawQ∗SF for each array, A and B.
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In the algorithm equations, liA and liB, represent the background corrected intensities of the
i-th probe pair from array A and B, respectively. As defined in the Affymetrix MicroArray Suite
(MAS) documentation, the significant difference threshold (SDT) is determined by the noise floor
of each array and the chosen scaling factor. The noise floor (rawQ) is calculated from the standard
deviation of the bottom 2% of the probe intensities across the array. The scaling factor (SF) for
each array is a multiplier that scales the median intensities to a target value (default is 500). The
gamma factor is set to 0.1 to prevent calculated Sscore values from being affected by gene ex-
pression levels (Zhang et al. 2002). The GCSscore package imports functions from the following
CRAN/BioConductor packages: BiocManager, Biobase, utils, methods, RSQLite, devtools, dplR,
stringr, graphics, stats, affxparser, and data.table. If it is desirable to pull datasets for GEO or per-
form the downstream analysis presented in this publication, the following additional packages are
necessary: siggenes, GEOquery, and R.utils. All probe-level data and annotations utilized by the
GCSscore package are parsed and sourced directly from the following chip specific BioConductor
packages: platform design (.pd) and AnnotationDbi (.db). The resulting probe-level data file is
packaged into a ‘probefile’ package, while the annotations are packaged into an additional ‘an-
not’ package. These packages are created on the fly and installed in the user’s library by utilizing
customized versions of the makeProbePackage function and package templates sourced from the
AnnotationForge package (Carlson and Obenchain 2015).
While the theory of the GCS-score method can be applied to any modern Affymetrix Ther-
moFisher chip type, the R package was written for use with Clariom-style arrays, which include:
ClariomS, ClariomD, and XTA assay chip types. This package fully supports all Clariom-style
arrays and has support for two of the most widely used 3’ IVT arrays: Mouse Genome 430 2.0 and
Human Genome UG133 2.0. For older types of Affymetrix arrays, the original sscore package must
be used. The GCS-score algorithm allows the user to calculate Sscore values for ClariomD/XTA
arrays using two probe grouping methods: (1) utilizes TCids groupings for gene-level, (2) utilizes
PSRids and JUCids for exon & alternate splicing-level. Since the ClariomS arrays only contain
TCids, there is only a gene-level analysis method. Additionally, for supported 3’ IVT chips, the
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method refers to two background subtraction options: (1) utilizes the new GC-bkg method (2)
utilizes the original PM-MM method. The GCSscore package allows for direct probe-level com-
parisons of two Affymetrix microarrays at a time. The user can either input two .CEL files directly
into the function, or read in a formatted batch file that is setup to run pair-wise comparisons of
multiple .CEL files in a single function call (see Table 5.1). For more information regarding the
implementation, please refer to the workflow diagram (see Figure 5.1). In brief: .CEL files are
scaled to have equivalent trimmed median intensities for the desired probe grouping method. The
Sscores are calculated and normalized using the middle 98% of the raw scores. Finally, normalized
results are combined with the annotation information parsed from the Bioconductor repository and
are returned to the user’s environment using the Biobase data structure, ExpressionSet. The user
can also choose to save the GCSscore results to disk, as a .CSV file.
5.2.2 Statistical properties and analysis of GCSscore outputs
One principal advantage of the S-score based methods is the simple Gaussian-like statistics
of the resulting output (see Figure 5.2). If no extreme differential expression exists between two
.CEL files then the GCSscore output will have a mean of 0 and a SD of 1 (Zhang et al. 2002).
Since, each run is essentially z-scored and normalized prior to output, each GCS-score becomes
a representation of the standard deviation from the mean of a Gaussian-like distribution. Thus,
the absolute values of S-scores greater than 1.8-2.0 are likely to be statistically significant and this
can be determined by using statistical testing of biological replicates with correction for multiple
testing, as done with the SAM method below.
5.2.3 Workflow for generating differential expression for downstream analysis
In our standard implementation, all treatment samples were run against all control samples in
a pairwise fashion. For example, if there are 3 replicates for the treatment and 3 replicates for
the control group, there will be 9 total pairwise comparisons (see Table 5.1). The Sscores were
averaged for each treatment sample against all 3 control samples, producing 3 averaged Sscore
values, one for each of the treatment samples. This was done to reduce noise with small sample
sizes and to prevent over inflation of sample numbers that would occur from taking all of the
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Figure 5.1: Workflow diagram for GCS-score algorithm.
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Figure 5.2: Example histogram for GCSscore output. Distribution of 785,000 exon targeted PSR
probesetids. Note the normal distribution of the Sscores (mean=0.002, SD=1.031)
Table 5.1: A typical pairwise comparison of a case with 3 treatment samples and 3 control sam-
ples. Also demonstrates the formatting and structure of the BATCH input for generating multiple
GCSscore comparisons in a single function call
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pairwise comparisons into account (Farris and Miles 2013). Alternatively, random pairings of
treatment/control samples can be used for generation of Sscores (Kerns et al. 2005). Differential
expression analysis with multiple-testing correction can then be applied.
For the statistical analyses presented in this publication, the averages of each treatment repli-
cate against all of the control samples were used as the input into a 1-class Significance Analysis of
Microarrays (SAM) analysis to identify genes with GCSscore values statistically different from 0,
as demonstrated in prior publications with the original S-score algorithm (Kerns et al. 2005; Wolen
et al. 2012; Farris and Miles 2013). The SAM algorithm used here was provided by the siggenes
package from Bioconductor. More complex experimental designs implement multiple group test-
ing in SAM or other appropriate statistical methods, such as LIMMA (Ritchie et al. 2015). The
average of these treatment replicate averages, denoted as AvgSs, was used as an additional stringent
filter to decrease contributions from genes with exceedingly small fold-changes, as reported pre-
viously (Kerns et al. 2005; Wolen et al. 2012; Farris and Miles 2013). To determine significantly
regulated gene lists, the following criteria were thus used: genes from the SAM output within a
determined FDR cutoff (e.g. 0.0125-0.1) and genes who also have |AvgSs| > 1.8. In the Clariom
array cases explored in Section 5.3.3 and Section 5.3.2, downstream analysis of the gene lists was
performed using ToppFun suite for Gene Ontology/Functional enrichment analysis and Ingenuity
Pathway Analysis (IPA) to find significantly altered signaling pathways. For the ToppFun analysis,
only the gene symbols from the generated gene lists were input directly into the suite. For the IPA
analysis, the TCids, AvgSs, and rawp values from the SAM output were used as the input.
5.3 Results
5.3.1 Comparison with original algorithm
Since the original S-score algorithm has been validated and utilized in previous publications,
we initially compared the GCS-score algorithm against the original S-score method. In this ex-
ample, previously published Mouse Genome 430 2.0 array data (GSE28515) from the prefrontal
cortex of DBA2/J mice is used (Wolen et al. 2012). We utilized 3 biological replicates exposed to
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acute i.p. ethanol (1.8 g/kg x 4 hours; treatment) and 3 biological replicates that received i.p. saline
(control). The GCSscore package and algorithm was completely rewritten from the ground up to
be much more efficient and add new functionalities. To confirm that the new algorithm performed
as expected, we analyzed these 430 2.0 arrays first using the PM-MM method found in the GC-
Sscore package with the original sscore package. For any given comparison between a treatment
and a control, GCS-score (PM-MM method) and the original S-score method produced identical
Sscore values (see Figure 5.3A), since the GCS-score algorithm simply utilizes individual MM
probes instead of the GC-content based background (GC-bkg). The new GC-bkg method was also
compared against the PM-MM method using the AvgSs metric described in Section 5.2. There was
considerable variation between the two methods as the AvgSs values approached zero, where there
was no detectable difference between treatment and the control groups (see Figure 5.3B). However,
convergence of the two methods was observed for Sscore values beyond an empiric significance
threshold of |AvgSs| > 1.8 (red lines in see Figure 5.3B). Previous studies have demonstrated that
DBA2/J mice have many more genes that are upregulated than downregulated, especially in the
medial prefrontal cortex (see Figure 3 from Kerns et al. 2005). This explains the dramatic skew
towards positive significant AvgSs values, regardless of the background subtraction method. The
results displayed in Figure 5.3 demonstrate that the new background subtraction method returned
very similar results to the original PM-MM method for significantly regulated genes, validating
the use of the new GC-based background subtraction method.
5.3.2 Comparison with RMA analysis of ClariomD/XTA assays
We then extended our characterization of GCS-score by comparing resulting analysis with
a traditional RMA analysis for ClariomD/XTA arrays. In this use case, the GCS-score results
were compared with RMA analysis results previously published in a study that utilizes ClariomD
mouse arrays (aka MTA 1.0) to study effects of chronic diazepam (DZP) administration on gene
expression in 3 mouse brain regions: cerebral cortex, hippocampus, and amygdala (Furukawa et al.
2017). The .CEL files used in the GCS-score analysis were pulled directly from the corresponding
GEO dataset: GSE76700. For the purposes of this analysis of the GCS-score algorithm, we limited
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Figure 5.3: Comparison of results for original S-score algorithm (y-axis) and the GCS-score al-
gorithm, using the PM-MM background correction method (x-axis). (B) Comparison of total av-
eraged GCSscores (AvgSs) on the 3’ IVT array, Mouse Genome 430 2.0 assay, for the GC-based
background correction (x-axis) and the legacy PM-MM method (y-axis). The red lines denote the
thresholds for significant Sscores (|AvgSs| > 1.8).
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comparisons to just cerebral cortex. There were 3 biological replicates in both the treatment (DZP)
and control group.
The original publication utilizes the standard workflow provided by Affymetrix’s Transcrip-
tome Analysis Console (TAC). Using statistical criteria without correction for multiple testing
(ANOVA uncorrected p-value ≤ 0.05 and |log2 fold change| ≥ 1.5), the authors identify 57 to-
tal transcripts regulated by chronic diazepam in cerebral cortex (see Suppl. Table 1 from Fu-
rukawa et al. 2017 ). Additionally, the reported PANTHER gene ontology enrichment results show
over-representation only for general large categories such as “binding” or “receptor activity” (see
Figure 1.C from Furukawa et al. 2017). Only one gene, Lipocalin-2 (Lcn2), from the cortex results
was replicated by quantitative PCR and used for further analysis, as it is the most strongly upreg-
ulated gene in all 3 brain regions investigated (Furukawa et al. 2017). Current literature reports
suggest that Lcn2 is implicated in innate immune responses via the sequestration of iron.
For the analysis of microarray data used the Furukawa publication, Sscores for the 3 treated
and 3 control .CEL files were generated in the pairwise fashion described in Implementation. This
results in 3 treatment replicate averages produced for each of 3 treatment sample against all of
the control samples. These 3 treatment replicate averages were used as the input for SAM sta-
tistical analysis. The GCS-score algorithm produced 432 transcripts with the following criteria:
SAM-based FDR ≤ .015 and |AvgSs| > 1.8. Thus, the GCS-score method was able to produce
many more significantly regulated transcripts with stringent multiple testing corrections, while
the published RMA/LIMMA approach generated much smaller gene lists using uncorrected p
values and modest fold changes produced from the standard TAC software. As expected, Lcn2
(TC0200003303.mm.1) had very large positive Sscores for all comparisons, which resulted in an
extremely high AvgSs = 17.21, replicating aspects of the results from the original publication.
Strikingly, over-representation analysis of GCS-score results with ToppFun produced multiple cat-
egories directly related to diazepam/GABA biology (see Table 5.2), as should be expected from
the experimental paradigm. GO categories of note included: drug binding, glutamate decarboxy-
lase activity, synaptic signaling, GABAergic synapse, and GABA synthesis. Pathway analysis of
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Figure 5.4: Fold change vs averaged GCSscore (AvgSs) for all publication-identified TCids in cere-
bral cortex from GEO dataset: GSE76700. The vertical red lines denote the significant threshold
for the averaged GCSscore values (|AvgSs| > 1.8). 50 of the 57 identified TCids are also detected
by the GCSscore method.
our GCS-score generated gene list via IPA produces multiple hits for immune-related signaling
pathways, which supported the original findings from (Furukawa et al. 2017), in the context of
the known functions of Lcn2 (see Figure 5.5). Importantly, the top 20 pathways produced by IPA
contained significant pathways for Glutamate degradation and GABA receptor signaling (see Fig-
ure 5.5). Furthermore, 50 of the 57 genes identified in Furukawa et al. 2017 had a study-wide
AvgSs > |1.8| and AvgSs values displayed a highly similar distribution to the originally published
log2 fold-change values (see Figure 5.4).
The original publication also investigates Lcn2 at the exon-level using the differential splic-
ing functionality of the TAC software. The MTA 1.0 array has 15 PSRids (8 targeting exons)
and 5 JUCids targeting splice junctions for the Lcn2 transcript (see Table 5.3). The authors of
the original publication deduce that the main transcript, Lcn2-201, is up-regulated rather than the
only other protein-coding transcript variant, Lcn2-206 (see Figure 4.A from Furukawa et al. 2017).
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Figure 5.5: Functional pathway enrichment for GCS-score results for GEO dataset: GSE76700.
Top 20 pathways returned from IPA
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Table 5.2: Functional GO enrichment for GCS-score results for GEO dataset: GSE76700. Top 5
enrichments for the listed GO categories returned from ToppFun GO Suite
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Figure 5.6: Exon- level GCGscores for Lcn2 expression in GEO dataset: GSE76700. GCSscores
for all PSRids assigned to Lcn2. The coverage segments of each PSRid is shown in the ‘PSR probe-
set model’ and in the highlighted segments of ‘PSR probeset GCSscores’ and ‘Ensembl transcript
variants’. Lcn2 is on the negative strand, so exon 1 is on the right and exon 6 is on the left. Ensembl
transcript variants that are ‘protein-coding’ are in red (Lcn2-201 and Lcn2-206). Figure demon-
strates that PSRids in the introns of the Lcn2-201 are all non-significant, while all Lcn2-201 exons
are upregulated. This rules out the non-coding transcript variants. There is significant upregulation
of exon 6 of Ln2-201, which is not present in the other protein coding transcript, Lcn2-206.
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Table 5.3: GCS-score results for all 15 exon-level probesetids assigned to Lcn2. Probesetids in
bold are either within an exon (PSR) or connect 2 exons (JUC).
Using the exon-level GCS-score method to analyze Lcn2, we found similar results to the original
publication. The GCS-score method found that all 8 PSRids targeting exons were significantly
upregulated, while none of the PSRids that targeted introns were altered (see Table-5.3 and Fig-
ure 5.4). Furthermore, all 5 of the JUCids were significantly upregulated in the GCS-score results.
The genomic location of PSRids targeting introns suggest that the transcripts with retained introns
(Lcn-202 to Lcn2-205) are unlikely to be regulated by the treatment (see Figure 4.A from Furukawa
et al. 2017). Additionally, both PSRids in the final exon of Lcn-201 (exon 6), are significantly up-
regulated via the GCS-score method. Since exon 6 is not found in Lcn2-206, we could not fully
eliminate the possibility of Lcn2-206 upregulation, but we confidently concluded that the main
transcript, Lcn2-201, was upregulated and that Lcn2 variants with retained introns were unlikely to
be altered by diazepam treatment. This demonstrates the utility of GCS-score exon-level method
for deducing which transcript variants are altered for the significantly regulated genes identified
by the GCS-score gene-level method. These results implied that the GCSscore package a valuable
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tool for both detecting significantly regulated genes and differential splicing analysis of exons for
ClariomD/XTA type arrays.
5.3.3 Comparison with RMA analysis of ClariomS assays
A final comparison illustrates use of the GCS-score vs. RMA/LIMMA methods for analysis
of published results with the ClariomS platform. As described in Wheeler et al. 2018, the original
study utilizes ClariomS mouse arrays to investigate differential gene expression of mouse microglia
cells 4 days after infection with the coronavirus, murine hepatitis virus (MHV). In this study, the
authors generate a gene list using an FDR cutoff of 0.05 and a linear fold change with an absolute
value greater than 2. The authors utilize IPA to produce enriched pathways for their significant
genes (see figure 1.C from Wheeler et al. 2018). The authors find that interferon (IFN) signaling
is the most upregulated pathway following infection, followed by 3 additional pathways linked
directly to the immune system (Wheeler et al. 2018). They also report the expression metrics of 29
select genes from their gene list that were highly upregulated (see figure 1.D from Wheeler et al.
2018). All microarray data related to the microglial analysis in the Wheeler publication is avail-
able in GEO dataset: GSE103380. For GCS-score analysis, all 4 naïve (control) samples and all
4 infected samples in the GEO dataset were investigated, leading to 16 total pairwise comparisons
of CEL files. As described above, the resulting 4 treatment replicate averages were interrogated
by a 1-class SAM analysis to detect Sscores not equal to 0. This resulted in 486 genes that passed
the determined selection criteria (FDR < 0.0125 and |AvgSs| > 1.8). The resulting gene list was
input into both IPA and ToppFun for functional over-representation analysis as described in the
Implementation section. The IPA analysis produced multiple pathways related to immune func-
tion, including the top pathways found in the original publication (see Figure 5.7). Of note, all
top 10 pathways from the GCS-score analysis are related directly to immune response and func-
tion, which is an even stronger implication of the biological functions observed in the original
published analysis (see Figure 1.C from Wheeler et al. 2018). Furthermore, 2 of the enriched path-
ways unique to the GCS-score results, “eIF2 Signaling” and “role of PKR in Interferon Induction
and Antiviral Response”, are likely upstream of the interferon signaling pathways identified in both
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methods. Recent literature has demonstrated that eIF2-alpha is integral for maximum production
of inflammatory cytokines and type I interferons in response to microbial infection (Pierre 2019).
This suggested that the GCS-score method was also able to identify potential important additional
biological functions related to this experimental design. The ToppFun analysis was consistent with
the IPA data, showing major enrichment for categories related to immune response and modulating
interferon production during a viral infection (see Table 5.4). Additionally, AvgSs values displayed
a high degree of correlation (see Figure 5.8) with the linear fold change values for significantly
regulated genes identified by the authors of the original manuscript (S. Perlman, personal commu-
nication; data not shown). Finally, 24 of the 29 (83%) of the selected upregulated genes highlighted
in the original publication (Figure 1.D from Xu et al. 2011) were also contained in the GCS-score
derived gene list, demonstrating good overlap between the methods when the comparing the most
differentially regulated transcripts that are identified by either method.
Figure 5.7: Top 10 enriched pathways via Ingenuity Pathway Analysis (IPA) for GCS-score
analysis of GEO dataset: GSE103380
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Figure 5.8: Correlation of AvgSs values with reported linear fold change (FC) for dataset:
GSE103380. The vertical red lines denote the thresholds for significant Sscores (|AvgSs| > 1.8).
The horizontal red lines denote the threshold for significant linear fold changes (|Linear FC)| > 2).
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Table 5.4: Functional GO enrichment for GCS-score results for GEO dataset: GSE103380. Top 5
enrichments for the listed GO categories returned from ToppFun GO Suite
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5.4 Discussion
Here we have described a new software methodology for analysis of the latest generation
of Affymetrix/ThermoFisher microarrays, based upon a re-derivation of our original S-score al-
gorithm that allows analysis of current oligonucleotide microarray platforms. Since microarray
technology has inherent advantages for certain genomic studies compared to RNAseq, on the basis
of costs and time required for analysis, such methodology development is of considerable sig-
nificance. Furthermore, microarray studies continue to be utilized for thousands of publications
in the published literature each year, thus documenting a sizeable ongoing scientific contribution.
Our software development is an outgrowth of the original S-score method for probe-level analysis
of Affymetrix arrays which has been previously validated as a sensitive method for differential
gene expression analysis that was particularly valuable for studies employing low numbers of
replicates (Zhang et al. 2002; Kennedy, Archer, and Miles 2006). Here we have presented three
use cases to demonstrate that our new R package software and analysis algorithm, GCS-score,
can provide analysis results equal to the prior S-score method for older generation (3’ IVT) mi-
croarrays, while delivering substantial benefits compared to existing methods for analysis of the
newest ClariomS/ClariomD/XTA arrays. We demonstrated that for 3’ IVT arrays, GCS-score pro-
duced very similar differential gene expression analysis results compared to the original S-score
method, which had been validated against multiple other algorithms, including RMA (Kennedy
et al. 2006). We also found that the GCS-score method produced similar results to the existing
RMA/LIMMA method for the ClariomS arrays. The results presented here suggest that GCS-score
provides greater sensitivity for detection of DEG gene lists for the ClariomS assay, as evidenced
by results of the IPA and ToppFun enrichments. In particular, the GCS-score method may provide
more relevant pathways, including two potential upstream regulators of the interferon signaling
identified in (Wheeler et al. 2018). Additionally, GCS-score produced a larger gene set than the
methods used in (Xu et al. 2011) when using similar statistical thresholds (S. Perlman, personal
communication; data not shown). Finally, we showed that GCS-score was far superior to the tra-
ditional RMA/LIMMA approach for analysis of ClariomD/XTA based studies. The GCS-score
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algorithm was able to identify many significantly regulated transcripts that survived multiple test
correction, while the RMA/LIMMA method returned very few transcripts, even with uncorrected
p-values. Importantly, the GCS-score method led to increased biological insight that was consistent
with the studied treatment, as evidenced by identification of multiple gene sets over-represented
with functional groups and pathways related to GABA biology, as would be expected when pro-
filing the cortex of chronically Diazepam-treated animals. In addition, the GCS-score exon-level
analysis was capable of providing critical details regarding the regulation of individual transcript
variants in genes that show significant regulation at the gene-level. Although not the object of this
report, it is peculiar that the RMA/LIMMA methods appeared to work satisfactorily with ClariomS
platforms, but failed to function sensitively for ClariomD/XTA assays. The ClariomS array is de-
rived from the accompanying ClariomD/XTA array for each species (mouse, rat, human). In fact,
multiple publications that use ClariomD/XTA arrays only report uncorrected p-values due to this
limitation (Pierre 2019; Wolstenholme et al. 2017). The ClariomS arrays are composed of probes
taken directly from the corresponding ClariomD/XTA array but utilizes only the 10 best performing
probes for TCids that code for well annotated genes producing at least one protein-coding variant.
Thus, ClariomD/XTA arrays target many more noncoding transcripts than protein-coding tran-
scripts. Non-coding TCids on ClariomD/XTA arrays are the predominant probe type and tend to
be expressed at very low or high levels compared to protein-coding gene probes (data not shown).
We suggest that the LIMMA analysis of log2 RMA intensities from ClariomD/XTA arrays may
be affected by the overwhelming number of noncoding transcripts found in these low and high
intensity distributions. This disparate signal distribution might alter the normalization of RMA
intensity results and thus increase signal/noise variance and thereby reduce statistically signifi-
cant results from FDR analysis of these arrays. GCS-score is immune to this effect since it only
considers the relative changes for each individual TCid/PSRid when making comparisons. These
individual TCid/PSRid comparisons are independent of each other, so the coding transcripts are
unaffected by the noncoding transcripts. Furthermore, we demonstrated that GCS-score is able to
produce significant results for the ClariomD/XTA arrays with as few as 3 control and 3 treatment
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arrays, which reduces the time and costs of genomic experiments that utilize this technology. These
properties make the GCS-score method a powerful analysis tool for the most advanced array tech-
nology available on ClariomD/XTA arrays, as well as the ClariomS arrays. The new methodology
described here also further supports the inherent strengths of the probe-level analysis provided by
the GCS-score algorithm.
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Chapter 6
Discussion, Conclusions, and Future Directions
6.1 Ethanol and Expression of Ndrg1 in Oligodendrocytes
One of the most troubling questions regarding alcohol consumption is what drives some indi-
viduals to develop maladaptive and compulsive escalation of consumption of ethanol while other
individuals are unaffected by early and even fairly regular consumption. As discussed in Chapter 2
and shown in Figure 2.1, basal levels of myelin expression in the frontal cortex are thought to
play a role in acute behavioral sensitivity to ethanol, which is a risk factor for AUD, and myelin
expression responses to ethanol are hypothesized as integral to the pathophysiology of brain mal-
adaptation during chronic ethanol consumption (Schuckit et al. 1994; Costin and Miles 2014).
Strong alterations in myelin related gene expression following ethanol exposures have been de-
tected in both animal models and post-mortem human tissue (Lewohl et al. 2000; Kerns et al.
2005; Farris and Miles 2013; Bogenpohl et al. 2019). The genes that have been replicated across
multiple studies and animal models, and the genes that have the strongest connectivity to other
myelin related genes are promising candidates for mechanistic study in gene-targeted models of
AUD. In studies described here, one such myelin-related gene, Ndrg1, was identified as a potential
candidate gene that modulates ethanol-induced changes in myelin-related gene expression, acute
behavioral sensitivity to ethanol, and long term ethanol consumption behavior.
This dissertation began by studying the localization of the NDRG1 protein within the mPFC,
in terms of both cell type and sub-cellular localization. Here, our goal was to determine if NDRG1
was expressed in mPFC neurons, in addition to the known high expression in oligodendrocytes,
given the preliminary lentiviral NDRG1 knockdown results described in Chapter 2. Those prelim-
inary studies did not fully characterize the cellular site of lentiviral expression but it was presumed
to largely be in neurons based upon preliminary immunolabeling of the injection site (see Fig-
ure 3.2). It was thus presumed that some NDRG1 expression must occur in neurons to explain
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the alterations in ethanol behaviors seen after mPFC viral transduction. However, we ultimately
determined that Ndrg1 expression was exclusively within oligodendrocytes in the mPFC and likely
the whole of the CNS, at least at the level detectable by immunofluorescence. This suggests that
perhaps the lentiviral knockdown experiments described in Chapter 2 were altering Ndrg1 expres-
sion in oligodendrocytes, since lentiviral vectors have been used to transduce multiple brain cell
types. Single cell sequencing or qPCR would be a more sensitive technique to resolve this question
ultimately. We also found that the localization of Ndrg1 to cellular compartments or the myelin
processes varied with phosphorylation at two different sites that are both phosphorylated by ethanol
responsive kinase, Sgk1. Based on these findings, we wanted to explore how Ndrg1 transcript and
protein variants were altered by both acute and chronic ethanol.
6.2 Ethanol Modulates Ndrg1 Expression Patterns
Previous works have shown that Ndrg1 transcript and phosphorylation levels in the mPFC are
altered following acute ethanol exposure in DBA2/J male mice (Kerns et al. 2005; Costin, De-
ver, and Miles 2013). However, the effects of chronic ethanol exposure on Ndrg1 had not been
previously studied prior to this work. Additionally, we conducted a more extensive probing of
Ndrg1 transcript and protein dynamics following acute ethanol. Furthermore, we also performed
our studies in the C57BL/6J mouse strain to characterize Ndrg1 responses in a strain widely used
for studies on ethanol consumption behavior. DBA2/J mice consume only low levels of ethanol
(Yoneyama et al. 2008). We found that acute ethanol induced Ndrg1 transcript in the mPFC in fe-
male C57BL6/J mice at the highest ethanol dose (4 g/kg, i.p.), but not in male mice. Additionally,
we observed a dose dependent decrease in levels of thr346-pNDRG1 in both sexes of mice follow-
ing acute ethanol. Furthermore, we found a change in the nuclear/cytosol ratio of ser330-pNDRG1
in oligodendrocytes following acute ethanol (2 g/kg, i.p.) in male mice.
Conversely, little change in NDRG1 protein expression or phosphorylation was detected fol-
lowing chronic ethanol exposure. We recorded a significant induction of Ndrg1 transcript in the
mPFC following the 2-bottle choice drinking study, but failed to detect any changes in total or
phospho-protein levels in the mPFC. Future works should follow-up with an IHC-based study to
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detect any changes in the nuclear/cytosol ratio of pNDRG1 are present after chronic ethanol drink-
ing. Evidence in Hela cells has suggested that the phosphorylation state as determined by elec-
trophoretic mobility, from action of both Sgk1 and Gsk3β , plays a role in the function of NDRG1
(Murray et al. 2004). While this group did not detect any changes of pNDRG1 localization in HeLa
cells, others have reported the different phospho-forms of NDRG1 can display both cytoplasmic
and nuclear localization (Lachat et al. 2002). As of the time of this dissertation work, neither the
physiological functions of nuclear vs. cytoplasmic NDRG1 nor the role that phosphorylation plays
on these functions is well understood.
One potentially interesting follow-up would be to design antibodies that target some of the
residues that are phosphorylated by Gsk3b, since there are no commercially available antibodies
that target residues phosphorylated by this kinase. However, we did not see any larger bands
or true doublets when staining for NDRG1 following acute or chronic ethanol exposure, as was
observed by Murray et al. 2004. This suggests that large changes in levels of GSK3B mediated
phosphorylation of NDRG1 are not likely to occur following ethanol exposures.
6.3 Ndrg1 Levels Modulate Ethanol-Related Behaviors
After characterizing the response of mPFC Ndrg1 expression following both acute and chronic
ethanol, the next major aim of this work investigated the effects of Ndrg1 modulation in the myelin
producing cells of the nervous system. Earlier preliminary lentiviral data demonstrated that knock-
down of mPFC Ndrg1 altered sensitivity to acute ethanol and shifted consumption to lower ethanol
concentration solutions. Localization of the lentiviral vector expression suggested mainly neuronal
localization (Figure 3.2), but close inspection of that data does identify occasional lentiviral expres-
sion in NeuN- cells (see Figure 3.2). Based upon data from the first aim of this thesis project, we
were confident that Ndrg1 expression was limited to oligodendrocytes in the mPFC. We therefore
predicted that deletion of Ndrg1 in oligodendrocytes might produce similar results to the lentivi-
ral knockdown of Ndrg1 in terms of ethanol behaviors. In fact, we did find very similar drinking
behaviors regarding concentration preferences in a 3-bottle choice drinking model. It should be
noted that the current studies included both male and female mice while the lentiviral studies only
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utilized male mice. We did not replicate the acute ethanol sensitivity phenotype that was present in
the lentiviral knockdown. We found no change in duration of LORR, but we did see a suggestion
of a decrease in the onset time of the knockout mice. The LORR onset results do suggest that
acute sensitivity to ethanol is in fact increased, while the acute functional tolerance is unchanged
as indicated in the LORR duration data.
Several options exist to explain the apparent discrepancy between the prior lentiviral NDRG1
knockdown studies and the current studies reported in this thesis. It could be that the lentiviral
shRNA is interacting with something off target in neurons to alter ethanol behavioral, since neurons
were the overwhelming infected cell type in IHC validation (see Figure 3.2). However, as noted
above, the lentiviral studies did appear to infect at least some non-neuronal cells. Unfortunately,
further cell-type characterization of such cells was not done at the time. It could also be possible
that the current studies producing a global knockout of Ndrg1 in all myelinating cells resulted in
a confounding behavioral phenotype that could be driving some of our results. It would also be
worthwhile to conduct a LORR study at 3-6 months following the knockout of Ndrg1, instead of
just one month. If there is a degradation of myelin function that is not recoverable following a
re-population of Ndrg1-positive oligodendrocytes, then we could expect to see worse performance
in the LORR challenge.
Additionally, the possible effect of the peripheral nerve dysfunction on the Ndrg1 global
myelin knockout cannot be ignored when considering the ethanol-related behaviors. Increased
tactile hypersensitivity in the knockout could, for example, modify ethanol behaviors. A strong
followup to this work would include experiments with a newly generated Ndrg1-floxed mouse
line. Here, a Cre-expressing virus targeted to oligodendrocytes or neurons could be precisely de-
livered into the mPFC region by stereotactic injection. This would be of great use to help determine
if the peripheral effects of Ndrg1 deletion or the deletion of Ndrg1 in other brain regions or cell
types is driving some of our behavioral data.
118
6.4 Ndrg1 Levels Modulate Peripheral Nerve Function
The effects of functional deletion of Ndrg1 on the peripheral nervous system has been doc-
umented throughout this work. Previous studies with Ndrg1 mutations or deletions in mice and
humans have demonstrated that peripheral myelination proceeds normally until adolescence be-
gins. The degradation of myelin at this later stage led experimenters to suggest that Ndrg1 deletion
leads to myelin degradation during myelination bursts in particular (Okuda et al. 2004). In this
work, we generated a novel mouse line that allowed us to delete Ndrg1 in adult mice following the
myelination burst that occurs in adolescence. Ultimately, we found that deletion of Ndrg1 led to
rapid and permanent development of very high levels of mechanical and thermal sensitivity. We
found that both the velocity and the amplitude of sciatic nerve conduction was diminished in Ndrg1
knockout mice 6 months post deletion. This demonstrated that ongoing expression of Ndrg1 is in
fact essential for the maintenance of peripheral myelin and axonal function.
Additionally, we used our animal model to show that knockout mice that receive low doses of
Paclitaxel shortly after the induction of Ndrg1 deletion develop mechanical sensitivity much more
rapidly than knockout mice that received vehicle or control mice treated with Paclitaxel. This
novel study provided crucial experimental validation of a clinical observation that nerve levels of
Ndrg1 in human breast cancer patients was inversely correlated with severity of Paclitaxel induced
neuropathy (Sundar et al. 2016).
In an effort to probe for cross-talk between the peripheral effects of Ndrg1 and high levels
of ethanol exposure, we attempted to ascertain if repeated high doses of ethanol could speed the
development of nerve dysfunction following Ndrg1 deletion. While we did not find any effect
of acute high doses of ethanol on the development of mechanical or cold sensitivity, it was a
limited experimental design that captured a very short time window. It could be that more chronic
exposures to ethanol are needed to further drive nerve dysfunction. For both the low dose Paclitaxel
and any additional ethanol exposure studies, it would be interesting to perform nerve conduction
velocity testing at the 6 month point following knockout. It would not be surprising to see further
deficits in both amplitude and velocity in knockout mice that received the experimental insults.
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Figure 6.1: Theories for role of Ndrg1 in modulation of acute ethanol sensitivity and normal myelin
function. Top: Overview of proposed mechanisms for modulation of acute sensitivity to ethanol
(left) and for the defects that occur in central myelin (right) following Ndrg1 deletion. Bottom:
Detailed view of proposed mechanism for modulation of ethanol sensitivity. Both NDRG1 and
KCNMA1 have been identified in the paranodal region of CNS axons and direct protein-protein
interactions (PPi) between KCNMA1 and NDRG1 have been observed. We propose that either
the direct PPi of NDRG1 and KCNMA1, or the modulation axonal lipid environment surrounding
KCNMA1 is responsible for the NDRG1-induced changes in acute ethanol sensitivity. Given that
Ndrg1 deletion did not change LORR onset or duration, we suggest that the possible Ndrg1 induced
modulation of the lipid content of the paranodal axonal membrane is more likely.
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6.5 Theories for Observed Effects of Ndrg1 Deletion
Given the number of diverse behavioral responses that are observed following Ndrg1 deletion,
it seems likely that multiple mechanisms are at play. Here, we suggest that two interconnected
mechanisms are driving the two noted phenotypes: peripheral nerve dysfunction and altered sen-
sitivity to ethanol. As described in detail in Chapter 2, there is ample evidence that Ndrg1 is
important for cellular bio-lipid metabolism. These deficits in metabolism in particular could be
why dysfunction does not occur until myelin production is dramatically up-regulated during the
myelination burst that occurs at adolescence. Thus, Ndrg1 may truly be critical for ongoing myelin
maintenance. Given the heavy lipid content of myelin, any deficits in lipid metabolism could result
in a loss of stability to the myelin ultrastructure (see Figure 6.1).
Prior works have found that loss of function mutations in the NDRG1 homolog in C. elegans
alters their acute functional tolerance to ethanol exposure (Farris et al., manuscript in preparation).
This is very interesting given that C. elegans do not contain any myelin, but instead have an al-
ternate glial-based support network for axons (Stout, Verkhratsky, and Parpura 2014). We know
from prior works that one of the main modulators of acute sensitivity to ethanol in C. elegans is
the Slo1 calcium-activated potassium channel activity (Kcnma1 in mice) along axons (Bettinger
and Davies 2014). In this publication, Bettinger and Davies also noted that many previous studies
had already determined that lipid environment surrounding the channel has large effects on the
channel sensitivity to ethanol. Furthermore, a previous study that utilized co-immunoprecipitation
with KCNMA1 as the bait found a unique protein-protein interaction with NDRG1, as shown in
Figure 6.1 (Kathiresan et al. 2009).
Based on our results and the findings in the literature, we propose that Ndrg1 affects the
bio-lipid synthesis of the myelin producing cells and thus the lipid composition of myelin. NDRG1
is also localized to the myelin lamellar membrane processes, and it perhaps influences the traffick-
ing of lipids to the myelin process. The lipid composition on the interface between the axon and
the adjacent myelin membrane is responsible for the normal function and response of BK channels
on the axon (see Figure 6.1), particularly in the presence of ethanol. In this way, the effect of Ndrg1
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on lipid metabolism and trafficking is driving the degradation of peripheral nerve function as the
Schwann cells cannot meet lipid demands. Conversely, in the CNS, Ndrg1-induced alterations in
lipid dynamics of oligodendrocytes might directly modulate the BK channels along axons, which
could result in significant changes in the sensitivity of the BK channel response to ethanol.
To begin testing these theories, it would be useful to utilize confocal IHC to determine overlap
of anti-KCNMA1 antibody along axons with the anti-NDRG1 antibody along the myelin pro-
cesses. We predict that a noted co-localization of these proteins will occur along the myelin
process-axon junction. It would also be of interest to stain with additional markers, such as sodium
channels, to further understand how Ndrg1 interacts with various compartments of the axon it sur-
rounds. Additionally, it is remarkable how much more severe (in terms of myelin structure) the
peripheral effects of Ndrg1 deletion are than the central effects. It is unknown if different pathways
are affected or if compensatory mechanisms exist in the CNS relative to the PNS. We propose a
microarray/RNAseq experiment that will analyze the transcriptome response to knockout of Ndrg1
in both sciatic nerve and in the mPFC. The genomic study should help dissect which pathways and
mechanisms are most affected in each region, providing a more clear understanding of the role of
Ndrg1 in both the PNS and the CNS.
6.6 Concluding Remarks
The work presented in this dissertation sought to illuminate the frontal cortex response to
ethanol in relation to Ndrg1 expression and how Ndrg1 deletion alters ethanol-related behaviors.
We also sought to answer questions of how temporal knockout of Ndrg1 produces its most well
characterized phenotype: peripheral neuropathy. Our findings demonstrate that Ndrg1 expression
and functional state, as determined by phosphorylation and localization, are clearly modulated by
acute and/or chronic ethanol. We also found that deletion of Ndrg1 in myelinating cells alters
ethanol-related behaviors in a way that suggests sensitivity to ethanol is modified. The literature
and our results suggest that cellular bio-lipids and lipid interactions with BK channels, such as
Kcnma1, are key drivers for both the peripheral nerve dysfunction and the changes in ethanol
sensitivity, but more studies are needed to prove this hypothesis. We demonstrated the impor-
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tance of Ndrg1 for peripheral nerve function and that decreasing levels of Ndrg1 are a risk factor
for increased toxic effects of chemotherapeutics. Ultimately, the works presented here demon-
strate the biological importance of Ndrg1 in the maintenance of peripheral nerve function and as
an ethanol-related gene that modulates ethanol sensitivity, consumption, and risk for developing
AUD.
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